{"gene":"EGF","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1989,"finding":"EGF binding to EGFR triggers tyrosine phosphorylation of phospholipase C-II (PLCγ), which co-immunoprecipitates with the EGF receptor; this phosphorylation links EGFR tyrosine kinase activity to PIP2 hydrolysis and EGF-induced Ca2+ release. Tyrphostin kinase inhibitor blocks both PLC-II phosphorylation and its association with EGFR.","method":"Co-immunoprecipitation, phosphotyrosine immunoblotting, kinase inhibitor experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with functional validation (Ca2+ release blocked by kinase inhibitor), highly cited","pmids":["2472218"],"is_preprint":false},{"year":1980,"finding":"The EGF binding site of the EGFR is on the extracellular (external) face of the plasma membrane, while the phosphate acceptor (kinase substrate) site is on the cytoplasmic face, demonstrating the transmembrane topology of the receptor and that EGF-stimulated phosphorylation requires cell permeabilization for ATP access.","method":"Controlled proteolysis of intact vs. permeabilized cells, direct linkage cross-linking, 32P-ATP labeling with lysolecithin permeabilization","journal":"Journal of supramolecular structure","confidence":"High","confidence_rationale":"Tier 1 — biochemical reconstitution with direct experimental demonstration of transmembrane orientation","pmids":["6264233"],"is_preprint":false},{"year":1986,"finding":"EGF stimulates its own receptor synthesis: EGF treatment of WB hepatic cells increased EGFR mRNA levels 3–5-fold and stimulated new receptor protein synthesis within 2 hours, providing a positive feedback mechanism that counterbalances ligand-induced receptor degradation.","method":"Biosynthetic [35S]methionine labeling with immunoprecipitation, Northern blot with EGFR cDNA probes","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — two orthogonal methods (metabolic labeling + Northern blot) in a single study","pmids":["2420792"],"is_preprint":false},{"year":1986,"finding":"EGF and its receptor localize together within endosomal compartments (peripheral branching tubular network and pericentriolar multivesicular bodies) following EGF stimulation; the EGF-receptor complex redistributes from peripheral to pericentriolar endosomes in a temperature-dependent step before entering lysosomes.","method":"Immunoelectron microscopy with HRP-EGF and anti-receptor antibody-gold on A431 cells, frozen thin sections","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — direct subcellular localization by electron microscopy with functional temperature-dependence experiments","pmids":["2868013"],"is_preprint":false},{"year":1986,"finding":"The human EGF precursor is a 1,207 amino acid transmembrane protein with EGF flanked by large N- and C-terminal segments; it is expressed as a membrane protein with its N-terminus external to the cell surface, and its gene spans ~110 kb with 24 exons, suggesting exon duplication and shuffling in its evolution.","method":"cDNA sequencing, COS-7 cell transfection for expression, gene structure analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 — direct cDNA sequencing and expression in transfected cells, foundational structural characterization","pmids":["3491360"],"is_preprint":false},{"year":1987,"finding":"Overexpression of the EGFR in NIH 3T3 cells confers EGF-dependent transformation (focus formation, anchorage-independent growth) without altering basal growth, demonstrating that EGFR overexpression amplifies normal EGF signal transduction and is sufficient to drive oncogenic signaling in the presence of ligand.","method":"Eukaryotic expression vector transfection into NIH 3T3 and NR6 cells, focus formation assay, soft agar colony assay, DNA synthesis measurement","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with multiple phenotypic readouts, highly cited foundational paper","pmids":["3500791"],"is_preprint":false},{"year":1987,"finding":"EGF stimulates formation of inositol 1,4,5-trisphosphate (Ins-1,4,5-P3), Ins-1,3,4-P3, and Ins-1,3,4,5-P4, with concurrent decrease in PIP2, in A431 cells overexpressing EGFR and in five other EGFR-overexpressing cell lines, demonstrating EGF-induced activation of the phosphoinositide signaling pathway.","method":"Radiolabeled inositol phosphate measurement in multiple cell lines with EGFR overexpression","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — replicated across multiple cell lines in same study","pmids":["3030297"],"is_preprint":false},{"year":1988,"finding":"EGF stabilizes EGF receptor mRNA (prolonging its half-life), as well as β-tubulin and β-actin mRNAs, revealing a novel post-transcriptional mechanism by which EGF upregulates receptor expression distinct from the transcriptional mechanism of phorbol ester (PMA).","method":"mRNA decay assay with actinomycin D, Northern blot analysis","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 — direct mRNA stability measurement, comparison with PMA mechanism","pmids":["3260374"],"is_preprint":false},{"year":1989,"finding":"A specific 18-amino-acid highly negatively charged C-terminal domain of the EGFR (beyond the kinase domain) is required for EGF-dependent receptor internalization via a high-affinity saturable pathway and for ligand-stimulated cytosolic calcium increases, but kinase-active internalization-defective receptors can still signal gene transcription, morphological transformation, and growth.","method":"C-terminal deletion and truncation mutants expressed in cells, internalization assays, calcium measurement, transformation assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — multiple deletion mutants with multiple functional readouts, clearly dissects internalization from signaling domains","pmids":["2790960"],"is_preprint":false},{"year":1990,"finding":"EGF receptor autophosphorylation in living cells occurs by intermolecular cross-phosphorylation (transphosphorylation): a kinase-negative EGFR (K721A mutant) becomes tyrosine phosphorylated by co-expressed active EGFR upon EGF stimulation; the kinase-negative mutant acts as a dominant-negative to suppress mitogenic signaling.","method":"Coexpression of kinase-negative and C-terminally truncated active EGFR mutants, EGF-stimulated phosphorylation assay in living cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — elegant genetic epistasis with dominant-negative approach, direct demonstration of trans-phosphorylation","pmids":["2164634"],"is_preprint":false},{"year":1992,"finding":"Purified EGFR directly co-sediments with purified F-actin, identifying EGFR as an actin-binding protein. The actin-binding domain maps to amino acids 984–996 (sequence homologous to Acanthamoeba profilin actin-binding domain); a truncated EGFR lacking this region does not co-sediment with actin.","method":"Co-sedimentation assay with purified EGFR and F-actin, synthetic peptide competition, polyclonal antibody blocking, direct actin-binding assay with HL-33 peptide","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with purified proteins, domain mapping by peptide competition and antibody blocking","pmids":["1383230"],"is_preprint":false},{"year":1992,"finding":"EGF receptor internalization rate is stimulated ~50-fold at saturating EGF concentrations. High-affinity EGF binding requires the intact cytoplasmic domain; tyrosine kinase activity (Lys721) and the Thr654 region (PKC phosphorylation site) are required for the enhanced internalization of high-affinity receptors at low EGF concentrations.","method":"Kinetic binding and internalization assays with EGFR point mutants (K721A, T654A), phorbol ester treatment, blocking antibody experiments","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches with defined mutants and pharmacological tools","pmids":["1556153"],"is_preprint":false},{"year":1992,"finding":"PI 3-kinase p85 subunit associates with activated (autophosphorylated) EGFR via its SH2 domains; either N- or C-terminal SH2 domain of p85 is sufficient for receptor binding; receptor tyrosine autophosphorylation is required for p85 binding; p85 itself is not significantly tyrosine phosphorylated by EGFR, suggesting it acts as an adaptor.","method":"Co-immunoprecipitation, GST-SH2 domain pulldown, competitive binding with phosphotyrosine, anti-phosphotyrosine blotting","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal binding with domain mapping, multiple orthogonal approaches","pmids":["1372091"],"is_preprint":false},{"year":1993,"finding":"EGF receptor recycling occurs multiple times per receptor: A431 cells consume far more EGF molecules than the number of EGFR degraded or down-regulated, with apparent Michaelis-Menten kinetics for EGF consumption; individual EGFR recycle many times, consuming up to 45 EGF molecules per receptor over 6 hours.","method":"125I-EGF consumption assay at varying cell densities and EGF concentrations, comparison with receptor down-regulation rates","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — quantitative kinetic analysis with rigorous controls","pmids":["8416997"],"is_preprint":false},{"year":1994,"finding":"Sustained vs. transient MAP kinase activation determines differentiation vs. proliferation outcome downstream of EGF. Overexpression of EGFR in PC12 cells converts EGF from a mitogen to a differentiation factor by sustaining p42/p44 MAP kinase activity and inducing nuclear translocation of p42 MAP kinase.","method":"EGFR overexpression and dominant-negative mutant expression in PC12 cells, MAP kinase activity measurement, nuclear translocation assay, neurite outgrowth measurement","journal":"Current biology : CB","confidence":"High","confidence_rationale":"Tier 2 — multiple EGFR mutants with quantitative kinase activity and differentiation readouts, strong mechanistic dissection","pmids":["7953555"],"is_preprint":false},{"year":1997,"finding":"Gβγ subunits of Gi-coupled receptors mediate Src-dependent tyrosine phosphorylation of EGFR (transactivation) without receptor autophosphorylation; this involves Src family kinase recruitment to create phosphotyrosine docking sites for Shc/Grb2, forming a scaffold for Ras activation downstream of GPCRs.","method":"Dominant-negative c-Src and Csk expression, anti-phosphotyrosine immunoblotting, autophosphorylation-specific EGFR antibody, GST-Src-SH2 pulldown in COS-7 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including dominant-negative, phosphospecific antibodies, and domain pulldowns","pmids":["9020193"],"is_preprint":false},{"year":1998,"finding":"Oxidized LDL activates EGFR tyrosine phosphorylation in intact cells; 4-hydroxynonenal (4-HNE), a lipid peroxidation product, directly derivatizes and activates immunopurified EGFR in vitro, identifying EGFR as a sensor for oxidized lipids and establishing that chemical modification of EGFR can activate its kinase independently of ligand.","method":"Anti-phosphotyrosine immunoblotting in intact cells, in vitro kinase activation of immunopurified EGFR with oxLDL lipid extracts and 4-HNE","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 — both cell-based and in vitro reconstitution with purified receptor","pmids":["9619445"],"is_preprint":false},{"year":1999,"finding":"EGF receptor binding affinities to ErbB receptor dimers vary dramatically by combination: the ErbB2/4 heterodimer binds all EGF-domain ligands with moderate-to-high affinity, while ErbB3 shows highly restricted binding (only heregulin, neuregulin-2β, epiregulin, and the chimera biregulin); EGF binds ErbB1 but not ErbB4 alone; ErbB2 preferentially enhances ligand binding to ErbB3 or ErbB4.","method":"Soluble receptor-ligand binding assay with defined ErbB receptor combinations, competitive binding with EGF-domain proteins","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — systematic quantitative binding in defined reconstituted system with all combinations","pmids":["10214951"],"is_preprint":false},{"year":1999,"finding":"EGFR-ErbB2 heterodimerization impairs EGF-induced EGFR endocytosis: in breast cancer cells with high ErbB2/EGFR ratios, EGF-stimulated EGFR endocytosis is greatly inhibited; microinjection of ErbB2 expression plasmid into low-ErbB2 cells inhibits EGFR endocytosis; the endocytosis deficiency maps to ErbB2's intracellular domain.","method":"Subcellular fractionation, co-immunoprecipitation, indirect immunofluorescence, microinjection of ErbB2 expression plasmid, ErbB2/EGFR chimera endocytosis assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, domain mapping with chimeric receptor, replicated in four cell lines","pmids":["10233167"],"is_preprint":false},{"year":1999,"finding":"EGF crosses the blood-brain barrier rapidly (influx rate ~2 μl/g·min) via a saturable transport system distinct from the EGFR; the transport is competed by unlabeled EGF and TGF-α but not by anti-EGFR antibody or by EGFR mutation, suggesting a separate EGF transport receptor at the BBB.","method":"Intravenous injection of 125I-EGF in mice with competition experiments; mice with EGFR mutations; TCA precipitation of brain-recovered peptide","journal":"Peptides","confidence":"Medium","confidence_rationale":"Tier 2 — saturation kinetics with competition experiments and genetic model","pmids":["10499427"],"is_preprint":false},{"year":2002,"finding":"The EGF receptor extracellular region exists in an autoinhibited 'tethered' conformation where the dimerization arm in domain II is occluded by intramolecular interactions with domain IV; EGF binding to domains I and III promotes a large domain rearrangement exposing the dimerization interface for receptor-mediated dimerization.","method":"X-ray crystallography at 2.8 Å of unliganded sEGFR extracellular region; mutagenesis validation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis validation, highly cited foundational structure paper","pmids":["12620237"],"is_preprint":false},{"year":2002,"finding":"Crystal structure of the 2:2 EGF:EGFR extracellular domain complex at 3.3 Å reveals: EGF docks between EGFR domains I and III; receptor dimerization occurs through a direct receptor-receptor interaction mediated by a protruding β-hairpin arm from domain II of each monomer; dimerization is receptor-mediated, not ligand-mediated. Validated by EGFR mutagenesis.","method":"X-ray crystallography at 3.3 Å resolution, EGFR mutagenesis to verify dimerization interface","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis, highly cited landmark structural paper","pmids":["12297050"],"is_preprint":false},{"year":2002,"finding":"Decorin binds to EGFR at a narrow region within the L2 domain (residues His394–Ile402) that partially overlaps with but is distinct from the EGF-binding site (K465 required for EGF but not decorin binding); decorin binding antagonizes EGFR tyrosine kinase. Central LRR6 of decorin mediates EGFR interaction.","method":"Decorin/alkaline phosphatase chimera, cDNA library expression cloning, yeast two-hybrid, EGF competition assays, EGFR deletion mutants, site-directed mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods including mutagenesis and expression cloning","pmids":["12105206"],"is_preprint":false},{"year":2002,"finding":"Cbl recruits CIN85 (constitutively bound to endophilins) to form a complex with activated EGFR upon EGF stimulation, controlling receptor internalization via clathrin-coated vesicles. This mechanism is functionally separable from Cbl's ubiquitin ligase activity: blocking CIN85-endophilin interaction inhibits EGFR internalization and delays degradation without affecting receptor ubiquitination.","method":"Co-immunoprecipitation, dominant-negative and siRNA approaches, internalization assays, ubiquitination assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with multiple orthogonal methods separating ubiquitination from endocytosis","pmids":["11894095"],"is_preprint":false},{"year":2002,"finding":"Cisplatin activates EGFR in a ligand-independent manner requiring EGFR kinase activity; this activation is mediated by c-Src kinases (blocked by Src inhibitor PP1 and dominant-negative kinase-dead receptor); EGFR activation by cisplatin represents a survival response, as EGFR inhibition enhances cisplatin-induced cell death.","method":"EGFR phosphorylation assays, kinase inhibitor (EGFR and Src), kinase-dead EGFR expression, cell death assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pharmacological and genetic tools, functional survival readout","pmids":["12483525"],"is_preprint":false},{"year":2002,"finding":"Laminin-5 domain III (DIII), liberated by matrix metalloproteinases during mammary gland involution, binds to EGFR and stimulates downstream MAPK signaling, MMP-2 gene expression, and cell migration. This ECM fragment functions as a cryptic EGFR ligand in tissue remodeling.","method":"Recombinant DIII binding to EGFR, downstream MAPK signaling measurement, MMP-2 expression, cell migration assay, TIMP-3 knockout mouse model","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — recombinant protein binding with functional readouts and in vivo validation in knockout mouse","pmids":["12695504"],"is_preprint":false},{"year":2002,"finding":"H. pylori induces HB-EGF gene expression and EGFR transactivation through the 'triple membrane passing signal' (TMPS): H. pylori triggers metalloprotease cleavage of surface HB-EGF precursor, releasing soluble HB-EGF that activates EGFR; this cascade requires metalloprotease, EGFR, and MEK1 activities and enhances IL-8 production.","method":"EGFR phosphorylation assays with metalloprotease inhibitors, HB-EGF gene expression analysis, IL-8 release measurement in gastric cancer cell lines","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — pathway inhibitor dissection with multiple readouts","pmids":["12099696"],"is_preprint":false},{"year":2002,"finding":"ADAM12 metalloprotease specifically sheds HB-EGF in cardiomyocytes stimulated by GPCR agonists; dominant-negative ADAM12 abrogates HB-EGF shedding and EGFR transactivation; KB-R7785 inhibitor binds ADAM12 directly; this pathway mediates cardiac hypertrophy. Identifies ADAM12 as the specific enzyme for cardiac HB-EGF shedding.","method":"ADAM12 cloning, dominant-negative expression, direct binding of KB-R7785 to ADAM12, EGFR phosphorylation, cardiac hypertrophy model in mice","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods including dominant-negative, direct binding, and in vivo mouse model","pmids":["11786904"],"is_preprint":false},{"year":2003,"finding":"SHP2 acts upstream of Ras in EGFR signaling by dephosphorylating RasGAP binding sites at the plasma membrane (specifically Tyr992 of EGFR), preventing RasGAP membrane translocation and thereby extending the half-life of GTP-Ras and enhancing Ras-dependent mitogenic signaling.","method":"Dominant-negative SHP2, EGFR Y992F point mutation, RasGAP translocation assay, GTP-Ras half-life measurement","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — site-directed mutagenesis of specific EGFR residue with mechanistic pathway analysis","pmids":["14560030"],"is_preprint":false},{"year":2003,"finding":"CAML (calcium-modulating cyclophilin ligand) directly associates with the kinase domain of EGFR in a ligand-dependent manner and is required for efficient recycling of internalized EGFR to the plasma membrane; CAML-deficient cells show impaired EGF-induced proliferation despite normal EGF-induced signaling and internalization.","method":"CAML gene disruption in mice, EGF-stimulated proliferation assay, EGFR internalization assay, direct CAML-EGFR association by co-immunoprecipitation","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 — genetic knockout with mechanistic follow-up showing direct protein interaction","pmids":["12919676"],"is_preprint":false},{"year":2003,"finding":"Gab1 associates with EGFR at pTyr1068 and pTyr1086 in the receptor C-tail; Gab1 overexpression potentiates EGF-induced MAPK and JNK activation; PI3K (via its product PtdIns(3,4,5)P3 binding to Gab1 PH domain) acts as both upstream regulator and downstream effector of Gab1, creating a positive feedback loop; PTEN lipid phosphatase blocks this loop.","method":"Co-immunoprecipitation, GST-pulldown mapping, dominant-interfering p85, Wortmannin, PH domain-PIP3 binding, PTEN expression, GFP-Gab1 translocation imaging","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal approaches defining site of interaction and positive feedback mechanism","pmids":["10648629"],"is_preprint":false},{"year":2003,"finding":"EGF-induced actin polymerization remains locally restricted at the site of EGF bead stimulation (requires Arp2/3 complex and cofilin, independent of PI3K and Rho), while EGF-induced ERK activation spreads throughout the cell, demonstrating spatially distinct signaling scales from locally stimulated EGFR.","method":"Biotin-EGF streptavidin magnetic bead local stimulation, actin polymerization assay, PI3K and Rho inhibitors, Arp2/3 and cofilin functional analysis, ERK activation imaging","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — novel local stimulation approach with multiple pathway inhibitor experiments","pmids":["12952932"],"is_preprint":false},{"year":2004,"finding":"Acetylcholine triggers mitochondrial ROS generation in cardiomyocytes via sequential metalloproteinase-dependent shedding of HB-EGF from the proHB-EGF precursor, followed by EGFR transactivation and PI3K activation; blocking metalloproteinase, HB-EGF (with CRM-197), or EGFR abrogates ROS generation and cardioprotection in intact hearts.","method":"MitoTracker Red fluorescence, metalloproteinase inhibitor III, CRM-197 HB-EGF inhibitor, anti-HB-EGF neutralizing antibody, EGFR phosphorylation in perfused hearts, infarct size measurement","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pathway inhibitors in both cell and intact heart models","pmids":["15010282"],"is_preprint":false},{"year":2005,"finding":"Cetuximab inhibits EGFR by binding exclusively to domain III of the EGFR extracellular region (in its autoinhibited tethered conformation), partially occluding the EGF ligand-binding region and sterically preventing the receptor from adopting the extended conformation required for dimerization.","method":"X-ray crystallography at 2.8 Å of cetuximab Fab–sEGFR complex","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure defining precise mechanism of antibody inhibition","pmids":["15837620"],"is_preprint":false},{"year":2005,"finding":"Nuclear EGFR physically interacts with STAT3 in the nucleus, and this complex directly activates transcription of the iNOS gene; nuclear EGFR abundance positively correlates with iNOS levels in breast carcinomas; this reveals a transcription factor mode of action for nuclear EGFR requiring STAT3 as a DNA-binding co-factor.","method":"Co-immunoprecipitation of nuclear EGFR and STAT3, chromatin immunoprecipitation, reporter gene assays, IHC in breast carcinomas","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — ChIP + Co-IP + reporter assay + in vivo correlation, multiple orthogonal methods","pmids":["15950906"],"is_preprint":false},{"year":2005,"finding":"Lung cancer EGFR mutations (L858R, G719S) activate EGFR by disrupting autoinhibitory interactions between the activation loop and αC helix in the kinase domain; L858R accelerates catalysis up to 50-fold in vitro; gefitinib binds 20-fold more tightly to L858R mutant than wild-type; crystal structures show similar inhibitor binding modes for gefitinib and AEE788 but a staurosporine rotation in G719S.","method":"Crystal structures of mutant kinases with inhibitors, in vitro kinase activity measurement, direct binding measurements by fluorescence","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structures + in vitro kinase assays + direct binding measurements, highly cited","pmids":["17349580"],"is_preprint":false},{"year":2006,"finding":"Somatic EGFR mutations found in gefitinib-sensitive NSCLC (e.g., L858R, exon 19 deletions) cause EGF-independent constitutive EGFR signaling; mutant receptors at the cell surface are fully competent to bind EGF; mutations predicted to disrupt activation loop-αC helix autoinhibitory interactions elevate ligand-independent kinase activity.","method":"Expression of EGFR mutants in null background (NR6 cells), EGF-independent Ba/F3 cell mitogenesis assay, tyrosine phosphorylation analysis, EGF binding assay","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — null background expression with functional mitogenesis and biochemical readouts","pmids":["16953218"],"is_preprint":false},{"year":2007,"finding":"Rabring7, a Rab7-interacting RING finger domain protein, has E3 ubiquitin ligase activity (preferentially using Ubc4/Ubc5 as E2 enzymes) and accelerates ligand-induced EGFR degradation; a catalytic mutant (C229S) inhibits cCbl-induced EGFR degradation, demonstrating Rabring7 participates in late endocytic trafficking of EGFR through its E3 ligase activity.","method":"In vitro ubiquitination assay with recombinant E1/E2/E3, RING domain mutagenesis, EGFR degradation assay with wild-type and C229S Rabring7","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro ubiquitination reconstitution plus cellular degradation assay","pmids":["17462600"],"is_preprint":false},{"year":2008,"finding":"EGF increases TRPM6 Mg2+ channel activity and plasma membrane surface expression through a pathway involving Src family tyrosine kinases and downstream Rac1; constitutively active Rac1 mimics EGF effects; dominant-negative Rac1 abrogates EGF-stimulated TRPM6 activity; the TRPM6 alpha-kinase domain is not required.","method":"Whole-cell patch-clamp recording of TRPM6, dominant-negative and constitutively active Rac1 expression, FRAP for TRPM6 mobility, Src inhibitor experiments in HEK293 cells","journal":"Journal of the American Society of Nephrology","confidence":"High","confidence_rationale":"Tier 2 — electrophysiology + genetic tools (dominant-negative/constitutively active Rac1) + FRAP, multiple orthogonal methods","pmids":["19073827"],"is_preprint":false},{"year":2008,"finding":"ARAP1, a multidomain protein with Arf GAP and Rho GAP activities, localizes to endosomal compartments (including internal membranes of multivesicular bodies) and controls late steps of EGFR endocytic trafficking; ARAP1 knockdown causes EGFR accumulation in sorting/late endosomes and inhibits EGFR degradation with prolonged signaling.","method":"siRNA knockdown, ARAP1 localization by immunofluorescence/immunoelectron microscopy, EGFR trafficking and degradation assays","journal":"Traffic","confidence":"Medium","confidence_rationale":"Tier 2 — RNAi knockdown with defined trafficking phenotype and signaling readout","pmids":["18764928"],"is_preprint":false},{"year":2009,"finding":"The intracellular juxtamembrane domain of EGFR is required for both negative cooperativity in EGF binding and for the positive linkage between EGF binding and receptor dimerization; autophosphorylation abolishes the positive linkage but not cooperativity; this reveals inside-out signaling where intracellular events regulate extracellular ligand binding.","method":"Equilibrium EGF binding analysis with multiple EGFR mutants (juxtamembrane deletions, autophosphorylation site mutants), quantitative binding modeling","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — systematic mutant analysis with quantitative binding model","pmids":["19336395"],"is_preprint":false},{"year":2009,"finding":"Tom1L1 is transiently tyrosine-phosphorylated by Src family kinases upon EGF stimulation and forms a complex with activated EGFR bridged by Grb2 and Shc; Tom1L1 contains a novel clathrin-interacting motif in its C-terminal tail that engages clathrin heavy chain; RNAi knockdown of Tom1L1 inhibits EGFR endocytosis, identifying Tom1L1 as an adaptor linking activated EGFR to clathrin endocytic machinery.","method":"RNAi knockdown, co-immunoprecipitation, tyrosine phosphorylation assay, clathrin binding domain mapping, dominant-negative mutants","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — RNAi, reciprocal Co-IP, domain mapping, and functional rescue experiments","pmids":["19798056"],"is_preprint":false},{"year":2011,"finding":"Ganglioside GM3 strongly inhibits EGFR kinase domain autophosphorylation in a membrane context; this inhibition requires membrane phase separation and is released by removing GM3's neuraminic acid headgroup or by mutating EGFR membrane-proximal lysine K642G; GM3 prevents the allosteric transition from inactive to signaling EGFR dimer.","method":"Reconstitution of EGFR in proteoliposomes of defined lipid composition, autophosphorylation assay, headgroup modification, K642G mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — minimal reconstitution system with purified EGFR in defined lipid environment, mutagenesis validation","pmids":["21571640"],"is_preprint":false},{"year":2011,"finding":"IQGAP1 scaffold protein directly associates with EGFR (via its IQ domain binding to EGFR kinase domain) independent of EGF stimulation; calmodulin disrupts this interaction; IQGAP1-null cells show severely attenuated EGF-stimulated EGFR autophosphorylation; IQGAP1 S1443 (phosphorylated by PKCα downstream of EGFR) modulates EGFR activation.","method":"Co-immunoprecipitation (endogenous proteins), in vitro direct association assay, mass spectrometry phosphorylation mapping, IQGAP1 null cells with reconstitution, siRNA knockdown of PKCα","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — direct in vitro association + co-IP of endogenous proteins + null cell reconstitution + MS phosphorylation mapping","pmids":["21349850"],"is_preprint":false},{"year":2012,"finding":"The EGF transcriptional response is primarily elicited by EGFR at the cell surface, not from endosomes: keeping EGFR at the cell surface (by blocking endocytosis or ubiquitination) increases EGF-induced transcript abundance, while ESCRT depletion (trapping EGFR in endosomes with enhanced kinase activity) has little effect on the transcriptional profile.","method":"ESCRT depletion (siRNA), inhibition of EGFR endocytosis and ubiquitination, transcriptome profiling, kinase activity measurement","journal":"Science signaling","confidence":"Medium","confidence_rationale":"Tier 2 — systematic genetic perturbations of trafficking with transcriptome readout","pmids":["22416276"],"is_preprint":false},{"year":2012,"finding":"Annexin A1 interaction with S100A11 in endosomes is required for efficient lysosomal targeting of EGFR: a dominant-negative N-terminal truncation of annexin A1 (lacking both the EGFR phosphorylation site and S100A11 binding site) delays EGFR transport to LAMP1+ compartments and prolongs EGFR/MAPK signaling; S100A11 depletion produces the same trafficking defect.","method":"Dominant-negative annexin A1 mutant overexpression, S100A11 siRNA, EGFR trafficking assays, EGFR degradation and MAPK signaling measurements","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 — dominant-negative mutant + siRNA with parallel trafficking phenotypes","pmids":["23246849"],"is_preprint":false},{"year":2012,"finding":"Following EGF or ionomycin treatment, rhomboid intramembrane proteases (not γ-secretase) cleave the EGFR to produce a ~60 kDa intracellular domain (ICD) fragment present in both membrane and nuclear fractions; calpain inhibition increases detectable ICD levels; this regulated intramembrane cleavage occurs slowly over 3–24 hours.","method":"Chemical inhibitor profiling (γ-secretase vs. rhomboid inhibitors), rhomboid cDNA overexpression, calpain inhibitor, subcellular fractionation of ICD fragment in A431 cells","journal":"Traffic","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection combined with overexpression of specific protease","pmids":["22531034"],"is_preprint":false},{"year":2013,"finding":"Molecular dynamics simulations of membrane-embedded EGFR show that in ligand-bound dimers, extracellular domains favor N-terminal transmembrane helix dimerization and asymmetric (active) kinase dimer formation; in ligand-free dimers, extracellular domains favor C-terminal transmembrane dimerization, juxtamembrane burial, and symmetric (inactive) kinase dimers; electrostatic membrane interactions of the intracellular module are critical for this coupling.","method":"Molecular dynamics simulations of full-length membrane-embedded EGFR","journal":"Cell","confidence":"Low","confidence_rationale":"Tier 4 — computational prediction only, no direct experimental validation in this study","pmids":["23374350"],"is_preprint":false},{"year":2014,"finding":"EGFR is fully activated by EGF during mitosis (all five major tyrosine residues phosphorylated equivalently to interphase); however, in mitosis EGFR selectively activates PI3K, AKT2 (not AKT1), c-Src, c-Cbl, and PLCγ1 but cannot activate ERK1/2 because Raf-1 is not fully activated (lacks pY341, retains pS259); EGFR-dependent endocytosis during M phase requires EGFR kinase activity (unlike in interphase).","method":"EGF stimulation of synchronized mitotic cells, phosphorylation assays for EGFR and multiple downstream effectors, EGFR endocytosis assay in M phase vs. interphase","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 — systematic phosphorylation mapping of multiple effectors in synchronized cells","pmids":["25479591"],"is_preprint":false},{"year":2017,"finding":"EGFR ligands EGF, epiregulin (EREG), and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region; EREG and EPGN act as partial agonists of EGFR dimerization (inducing less stable dimers than EGF) and elicit more sustained EGFR signaling and differentiation-associated responses in breast cancer cells, rather than the proliferative response induced by EGF.","method":"X-ray crystallography of EGFR extracellular domain with different ligands, single-molecule imaging of EGFR dimerization, phosphorylation and signaling dynamics assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus single-molecule dimerization measurements plus functional signaling assays","pmids":["28988771"],"is_preprint":false},{"year":1999,"finding":"EGF-stimulated phosphorylation of histone H3 requires Rsk-2 (pp90rsk family kinase); fibroblasts from Coffin-Lowry syndrome patients (RSK-2 mutations) fail to show EGF-stimulated H3 phosphorylation; RSK-2 gene disruption in ES cells abolishes EGF-stimulated H3 phosphorylation; H3 appears to be a direct or indirect Rsk-2 target, linking EGF/MAPK signaling to chromatin remodeling.","method":"Coffin-Lowry patient fibroblasts, RSK-2 gene KO in ES cells, RSK-2 cDNA rescue, EGF stimulation with H3 phosphorylation assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — patient cells, gene knockout, and rescue experiments, multiple independent genetic approaches","pmids":["10436156"],"is_preprint":false},{"year":1983,"finding":"Human EGF/beta-urogastrone in plasma is associated with blood platelets: it is present in platelet-rich plasma and platelet fraction of whole blood; platelets contain both mature EGF and a high-molecular weight precursor form (cleaved to EGF by arginine esterase or trypsin); platelet-associated EGF is released during coagulation.","method":"Immunoaffinity chromatography extraction from plasma fractions, Sephadex G-50 gel chromatography, radioimmunoassay, radioreceptor assay, enzymatic cleavage","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical fractionation and characterization, highly cited foundational paper identifying EGF storage site in blood","pmids":["6603475"],"is_preprint":false},{"year":2019,"finding":"EGF triggers nuclear calcium signaling through PLCδ4 (not PLCγ1): nuclear EGFR hydrolyzes nuclear PI(4,5)P2 via PLCδ4, releasing InsP3 that activates InsP3 receptors on the nucleoplasmic reticulum to release Ca2+; nuclear Ca2+ signaling requires EGFR nuclear translocation; PLCδ4 and InsP3 modulate cell cycle progression by regulating cyclin A and B1 expression.","method":"Subcellular fractionation, siRNA knockdown of PLCδ4 and PLCγ1, FRET-based InsP3 biosensor, EGFR nuclear translocation inhibition, cyclin expression analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple knockdowns with FRET biosensor and cell cycle readout","pmids":["31537645"],"is_preprint":false},{"year":2020,"finding":"EGF/PKB-Akt signaling promotes FOXO4 degradation via a CSN6-COP1 axis: EGF treatment elevates CSN6 and COP1 levels; CSN6 binds FOXO4 and enhances COP1 E3 ligase activity toward FOXO4; COP1 directly interacts with FOXO4 via a VP motif and accelerates ubiquitin-mediated FOXO4 degradation; this reduces FOXO4-mediated suppression of serine-glycine-one-carbon (SGOC) metabolic pathway genes.","method":"Co-immunoprecipitation (CSN6-FOXO4 and COP1-FOXO4), ubiquitination assay, COP1 E3 ligase activity assay, ChIP for FOXO4 binding to SGOC gene promoters, metabolomic analysis","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP + in vitro ubiquitination + ChIP + metabolomics","pmids":["33101846"],"is_preprint":false}],"current_model":"EGF is a 53-amino-acid polypeptide (derived from a 1,207-aa transmembrane precursor) that binds to EGFR domains I and III, releasing intramolecular autoinhibition of the extracellular region and driving receptor-mediated dimerization via domain II β-hairpin arms; dimerization activates the asymmetric intracellular kinase, which transphosphorylates partner receptors on multiple C-tail tyrosines that serve as docking sites for SH2-domain adaptors (Grb2, Shc, p85/PI3K, PLCγ, SHP2, Gab1) to initiate Ras/MAPK, PI3K/Akt, PLCγ/Ca2+, and nuclear signaling cascades; receptor trafficking (clathrin-mediated endocytosis facilitated by Cbl-CIN85-endophilin and Tom1L1, recycling via CAML, late endosomal sorting by Rabring7/Rab7/annexin A1-S100A11, and rhomboid-mediated intramembrane cleavage) controls signal duration and amplitude; ligand identity (EGF vs. EREG/EPGN) determines dimer stability and signaling kinetics; membrane lipids (GM3 ganglioside) and scaffolds (IQGAP1, caveolin) modulate kinase activation; nuclear EGFR cooperates with STAT3 to activate iNOS transcription, and EGF-activated Rsk-2 phosphorylates histone H3 to remodel chromatin."},"narrative":{"teleology":[{"year":1980,"claim":"Establishing that EGF acts across the membrane resolved the fundamental topology question—EGF binds extracellularly while its receptor's kinase phosphorylates substrates cytoplasmically, defining EGFR as a transmembrane signaling conduit.","evidence":"Controlled proteolysis of intact vs. permeabilized cells with ³²P-ATP labeling","pmids":["6264233"],"confidence":"High","gaps":["Mechanism of transmembrane signal transduction unknown","Identity of kinase substrates unresolved"]},{"year":1983,"claim":"Discovery that platelets store both mature EGF and a high-molecular-weight precursor form revealed a physiological reservoir for circulating EGF and implied regulated proteolytic processing of the precursor.","evidence":"Immunoaffinity chromatography and radioimmunoassay of platelet-rich vs. platelet-poor plasma fractions","pmids":["6603475"],"confidence":"High","gaps":["Protease responsible for precursor cleavage in vivo not identified","Physiological significance of platelet-derived EGF release in wound healing not directly tested"]},{"year":1986,"claim":"Sequencing the full 1,207-residue EGF precursor and demonstrating its endosomal trafficking with EGFR established the biosynthetic origin and the post-binding itinerary of the ligand–receptor complex.","evidence":"cDNA sequencing with COS-7 expression (precursor structure); immunoelectron microscopy with HRP-EGF (endosomal co-localization)","pmids":["3491360","2868013"],"confidence":"High","gaps":["Proteolytic mechanism releasing 53-aa mature EGF from the precursor not identified","Signals controlling endosome-to-lysosome sorting not defined"]},{"year":1987,"claim":"Demonstrating that EGFR overexpression confers EGF-dependent transformation and that EGF activates phosphoinositide hydrolysis linked the ligand to both oncogenic potential and second-messenger generation.","evidence":"NIH 3T3 focus formation and soft-agar assays with EGFR overexpression; radiolabeled inositol phosphate measurement in multiple cell lines","pmids":["3500791","3030297"],"confidence":"High","gaps":["Downstream effectors of IP3/DAG pathway not mapped","Whether transformation requires specific signaling branches unknown"]},{"year":1989,"claim":"Identification of PLCγ as a direct EGFR substrate and mapping of a C-terminal internalization domain dissected the receptor's signaling outputs from its trafficking functions.","evidence":"Co-immunoprecipitation of PLCγ with EGFR plus tyrphostin blockade; C-terminal deletion mutant series separating internalization from transcription/transformation","pmids":["2472218","2790960"],"confidence":"High","gaps":["Full repertoire of EGFR C-tail phosphosites and their adaptor assignments incomplete","Relationship between internalization and signal termination untested"]},{"year":1990,"claim":"Proving that EGFR autophosphorylation occurs by intermolecular transphosphorylation established the dimerization-dependent activation paradigm and explained how kinase-dead receptors act as dominant negatives.","evidence":"Co-expression of kinase-negative K721A and C-terminally truncated active EGFR in living cells","pmids":["2164634"],"confidence":"High","gaps":["Structural basis for asymmetric kinase activation not yet resolved","Stoichiometry of higher-order oligomers unknown"]},{"year":1992,"claim":"Mapping PI3K p85 SH2-domain association with autophosphorylated EGFR and discovering a direct EGFR–F-actin interaction expanded the receptor's signaling repertoire to lipid kinase and cytoskeletal regulation.","evidence":"GST-SH2 pulldowns with phosphotyrosine competition (PI3K); purified EGFR–F-actin co-sedimentation with peptide competition and antibody blocking","pmids":["1372091","1383230"],"confidence":"High","gaps":["Functional significance of EGFR–actin binding in vivo not demonstrated","Specific EGFR phosphotyrosine residues docking p85 not mapped"]},{"year":1997,"claim":"Identification of Src-dependent EGFR transactivation by GPCR Gβγ subunits revealed that EGFR integrates signals from heterologous receptor systems, functioning as a signaling hub beyond its canonical ligand inputs.","evidence":"Dominant-negative Src and Csk overexpression, autophosphorylation-specific antibodies, GST-Src-SH2 pulldown in COS-7 cells","pmids":["9020193"],"confidence":"High","gaps":["Identity of metalloproteinase and shed ligand mediating transactivation not yet defined","Tissue specificity of transactivation pathway unknown"]},{"year":1999,"claim":"Systematic ligand-binding analysis across ErbB dimer combinations and discovery that EGF-stimulated Rsk-2 phosphorylates histone H3 defined both the combinatorial receptor logic and a direct chromatin-level output of EGF signaling.","evidence":"Soluble receptor–ligand binding with all ErbB combinations; Coffin-Lowry patient fibroblasts and RSK-2 knockout ES cells with EGF-stimulated H3 phosphorylation","pmids":["10214951","10436156"],"confidence":"High","gaps":["Genomic loci targeted by H3 phosphorylation downstream of EGF not identified","Whether partial agonist ligands also induce H3 phosphorylation untested"]},{"year":2002,"claim":"Crystal structures of unliganded (tethered) and EGF-bound (extended/dimerized) EGFR ectodomain resolved the autoinhibition-to-activation conformational switch at atomic resolution, answering how ligand binding triggers dimerization.","evidence":"X-ray crystallography at 2.8 Å (unliganded) and 3.3 Å (2:2 EGF–EGFR complex) with mutagenesis validation","pmids":["12620237","12297050"],"confidence":"High","gaps":["Full-length receptor structure in membrane context unavailable","Dynamics of tethered-to-extended transition unresolved"]},{"year":2002,"claim":"Multiple discoveries in 2002 defined how EGFR trafficking is controlled: Cbl–CIN85–endophilin complexes drive clathrin-mediated internalization separable from Cbl's ubiquitin ligase activity; SHP2 sustains Ras signaling by dephosphorylating RasGAP-binding sites; and GPCR-triggered metalloproteinase shedding of HB-EGF (by ADAM12) transactivates EGFR in cardiac and gastric contexts.","evidence":"Co-IP/siRNA/dominant-negative dissection of CIN85–endophilin; EGFR Y992F mutant with RasGAP translocation assay; dominant-negative ADAM12 in cardiomyocytes and metalloproteinase inhibitor profiling in gastric cells","pmids":["11894095","14560030","11786904","12099696"],"confidence":"High","gaps":["Whether CIN85 pathway is universal or cell-type-specific not resolved","Full substrate spectrum of SHP2 at the receptor unknown"]},{"year":2005,"claim":"Discovery that nuclear EGFR cooperates with STAT3 to activate iNOS transcription, and structural determination of how cetuximab locks EGFR in the tethered conformation, established both a non-canonical transcriptional role and the structural basis for therapeutic antibody blockade.","evidence":"ChIP + co-IP + reporter assays for nuclear EGFR–STAT3 on iNOS promoter; 2.8 Å crystal structure of cetuximab Fab–sEGFR complex","pmids":["15950906","15837620"],"confidence":"High","gaps":["Genome-wide target genes of nuclear EGFR–STAT3 undefined","How EGFR is imported into the nucleus mechanistically unclear"]},{"year":2006,"claim":"Characterization of NSCLC-associated EGFR mutations (L858R, exon 19 deletions) revealed they disrupt activation-loop autoinhibition to produce constitutive, ligand-independent kinase activity, and explained the hypersensitivity of these mutants to gefitinib.","evidence":"Crystal structures of L858R and G719S kinase domains with inhibitors; Ba/F3 EGF-independent mitogenesis; in vitro kinase assays showing 50-fold increased catalysis for L858R","pmids":["17349580","16953218"],"confidence":"High","gaps":["Resistance mutations (e.g. T790M) not structurally addressed in these studies","Whether all activating mutants share the same autoinhibition-disruption mechanism untested"]},{"year":2009,"claim":"Tom1L1 was identified as a clathrin-engaging adaptor linking EGF-activated EGFR–Grb2–Shc complexes to the endocytic machinery, adding a required component to the receptor internalization pathway.","evidence":"RNAi knockdown of Tom1L1 inhibiting EGFR endocytosis, reciprocal co-IP, clathrin-binding domain mapping","pmids":["19798056"],"confidence":"High","gaps":["Whether Tom1L1 is specific to EGFR or shared with other RTKs not tested","Structural basis of Tom1L1–clathrin interaction unresolved"]},{"year":2011,"claim":"Reconstitution of EGFR in proteoliposomes demonstrated that GM3 ganglioside inhibits the allosteric transition to the active kinase dimer through membrane-proximal lysine interactions, establishing membrane lipid composition as a direct regulator of receptor activation.","evidence":"Purified EGFR in defined-lipid proteoliposomes, autophosphorylation assay, K642G mutagenesis","pmids":["21571640"],"confidence":"High","gaps":["Physiological regulation of local GM3 concentration at the cell surface not addressed","Other lipid species potentially modulating EGFR not tested"]},{"year":2017,"claim":"Structural and single-molecule analyses showed that different EGFR ligands (EGF vs. EREG/EPGN) stabilize distinct dimer conformations of varying stability, directly determining signaling kinetics and cell-fate outcomes, thus establishing a 'biased agonism' paradigm for receptor tyrosine kinases.","evidence":"X-ray crystallography of ectodomain with multiple ligands, single-molecule dimer lifetime imaging, phosphorylation dynamics and phenotypic assays in breast cancer cells","pmids":["28988771"],"confidence":"High","gaps":["How dimer stability is decoded by intracellular signaling machinery not defined","Whether biased agonism extends to all seven EGFR ligands untested"]},{"year":2019,"claim":"Nuclear EGFR was shown to hydrolyze nuclear PI(4,5)P₂ via PLCδ4 to generate InsP₃ that triggers nucleoplasmic reticulum Ca²⁺ release, linking nuclear EGFR to cell-cycle progression through cyclin A/B1 regulation.","evidence":"siRNA knockdown of PLCδ4/PLCγ1, FRET-based InsP₃ biosensor, EGFR nuclear translocation inhibition, cyclin expression analysis","pmids":["31537645"],"confidence":"Medium","gaps":["Mechanism of EGFR nuclear import still unclear","Whether nuclear Ca²⁺ signaling occurs in non-transformed cells not shown","Single study; independent replication in other cell systems needed"]},{"year":null,"claim":"A complete structural model of full-length EGFR in its native membrane environment, integrating extracellular conformational switching with transmembrane helix dynamics, juxtamembrane regulation, and asymmetric kinase activation, remains unavailable; the precise mechanisms of EGFR nuclear import and the genome-wide transcriptional program of nuclear EGFR are unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No full-length membrane-embedded EGFR structure","Nuclear EGFR import mechanism unknown","Genome-wide nuclear EGFR target genes not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,5,6,14,21,49]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[20,21,49]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[51]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[4,51]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3,39]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,6,9,12,14,15,21,28,30,38,49]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[48,52]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[3,8,11,23,41]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,35,36]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[50]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[51]}],"complexes":[],"partners":["EGFR","PLCG1","PIK3R1","GRB2","SHC1","IQGAP1","ERBB2","GAB1"],"other_free_text":[]},"mechanistic_narrative":"EGF is a mitogenic polypeptide derived by proteolytic processing from a 1,207-amino-acid transmembrane precursor; it binds EGFR extracellular domains I and III, releasing an autoinhibited tethered conformation and exposing a domain II β-hairpin dimerization arm that drives receptor-mediated dimerization and asymmetric kinase activation via intermolecular transphosphorylation [PMID:12297050, PMID:12620237, PMID:2164634]. Receptor C-tail phosphotyrosines recruit SH2-domain adaptors (PLCγ, PI3K p85, Shc/Grb2, Gab1, SHP2) to activate Ras/MAPK, PI3K/Akt, and PLCγ/Ca²⁺ cascades, with signal duration—controlled by ligand identity, dimer stability, and receptor trafficking through clathrin-mediated endocytosis (via Cbl–CIN85–endophilin and Tom1L1) and recycling (via CAML)—determining whether EGF elicits proliferative or differentiative outcomes [PMID:2472218, PMID:1372091, PMID:10648629, PMID:7953555, PMID:11894095, PMID:19798056, PMID:28988771]. Membrane lipid environment (GM3 ganglioside inhibits the allosteric kinase transition) and scaffold proteins (IQGAP1) modulate activation thresholds, while nuclear-translocated EGFR cooperates with STAT3 to drive iNOS transcription and EGF-activated Rsk-2 phosphorylates histone H3 to remodel chromatin [PMID:21571640, PMID:21349850, PMID:15950906, PMID:10436156]. EGF is stored in platelets and released during coagulation, and its precursor is expressed as a cell-surface transmembrane protein whose biology is co-opted by GPCR transactivation pathways involving metalloproteinase-mediated shedding of HB-EGF [PMID:6603475, PMID:11786904, PMID:9020193]."},"prefetch_data":{"uniprot":{"accession":"P01133","full_name":"Pro-epidermal growth factor","aliases":[],"length_aa":1207,"mass_kda":134.0,"function":"EGF stimulates the growth of various epidermal and epithelial tissues in vivo and in vitro and of some fibroblasts in cell culture. Magnesiotropic hormone that stimulates magnesium reabsorption in the renal distal convoluted tubule via engagement of EGFR and activation of the magnesium channel TRPM6. Can induce neurite outgrowth in motoneurons of the pond snail Lymnaea stagnalis in vitro (PubMed:10964941)","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/P01133/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/EGF","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/EGF","total_profiled":1310},"omim":[{"mim_id":"621454","title":"MULTIVESICULAR BODY SUBUNIT 12B; MVB12B","url":"https://www.omim.org/entry/621454"},{"mim_id":"621453","title":"MULTIVESICULAR BODY SUBUNIT 12A; MVB12A","url":"https://www.omim.org/entry/621453"},{"mim_id":"621264","title":"FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA 1; FMAIT1","url":"https://www.omim.org/entry/621264"},{"mim_id":"621120","title":"DELTA-LIKE NONCANONICAL NOTCH LIGAND 2; DLK2","url":"https://www.omim.org/entry/621120"},{"mim_id":"621107","title":"HEMICENTIN 2; HMCN2","url":"https://www.omim.org/entry/621107"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"kidney","ntpm":102.9},{"tissue":"pancreas","ntpm":84.4},{"tissue":"skeletal muscle","ntpm":26.0}],"url":"https://www.proteinatlas.org/search/EGF"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P01133","domains":[{"cath_id":"2.120.10.30","chopping":"48-303","consensus_level":"medium","plddt":84.3511,"start":48,"end":303},{"cath_id":"2.10.25.10","chopping":"361-470","consensus_level":"medium","plddt":70.2176,"start":361,"end":470},{"cath_id":"2.120.10.30","chopping":"486-743","consensus_level":"high","plddt":88.1024,"start":486,"end":743},{"cath_id":"2.10.25.10","chopping":"749-779","consensus_level":"high","plddt":74.1094,"start":749,"end":779},{"cath_id":"2.10.25.10","chopping":"859-919_927-940","consensus_level":"medium","plddt":79.5573,"start":859,"end":940},{"cath_id":"2.10.25.10","chopping":"992-1025","consensus_level":"high","plddt":67.7685,"start":992,"end":1025}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P01133","model_url":"https://alphafold.ebi.ac.uk/files/AF-P01133-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P01133-F1-predicted_aligned_error_v6.png","plddt_mean":70.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=EGF","jax_strain_url":"https://www.jax.org/strain/search?query=EGF"},"sequence":{"accession":"P01133","fasta_url":"https://rest.uniprot.org/uniprotkb/P01133.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P01133/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P01133"}},"corpus_meta":[{"pmid":"10404636","id":"PMC_10404636","title":"EGF receptor.","date":"1999","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10404636","citation_count":814,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2472218","id":"PMC_2472218","title":"EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2472218","citation_count":785,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3500791","id":"PMC_3500791","title":"Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.","date":"1987","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/3500791","citation_count":636,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24295852","id":"PMC_24295852","title":"EGF receptor trafficking: consequences for signaling and cancer.","date":"2013","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24295852","citation_count":635,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7953555","id":"PMC_7953555","title":"EGF triggers neuronal differentiation of PC12 cells that overexpress the EGF receptor.","date":"1994","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/7953555","citation_count":441,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23374350","id":"PMC_23374350","title":"Architecture and membrane interactions of the EGF receptor.","date":"2013","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23374350","citation_count":419,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10214951","id":"PMC_10214951","title":"Binding specificities and affinities of egf domains for ErbB receptors.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10214951","citation_count":317,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10918300","id":"PMC_10918300","title":"The EGF receptor: a nexus for trafficking and signaling.","date":"2000","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10918300","citation_count":290,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17363253","id":"PMC_17363253","title":"Nimrod, a putative phagocytosis receptor with EGF repeats in Drosophila plasmatocytes.","date":"2007","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/17363253","citation_count":267,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8281612","id":"PMC_8281612","title":"EGF receptor in neoplasia and metastasis.","date":"1993","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/8281612","citation_count":258,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21571640","id":"PMC_21571640","title":"Regulation of human EGF receptor by lipids.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21571640","citation_count":249,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27635238","id":"PMC_27635238","title":"EGF receptor ligands: recent advances.","date":"2016","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/27635238","citation_count":246,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12695504","id":"PMC_12695504","title":"Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12695504","citation_count":237,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1383230","id":"PMC_1383230","title":"The EGF receptor is an actin-binding protein.","date":"1992","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1383230","citation_count":231,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9677101","id":"PMC_9677101","title":"EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma.","date":"1998","source":"Acta oncologica (Stockholm, Sweden)","url":"https://pubmed.ncbi.nlm.nih.gov/9677101","citation_count":216,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12105206","id":"PMC_12105206","title":"Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping but distinct from the EGF-binding epitope.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12105206","citation_count":194,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2420792","id":"PMC_2420792","title":"Epidermal growth factor (EGF) stimulates EGF receptor synthesis.","date":"1986","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2420792","citation_count":175,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10233167","id":"PMC_10233167","title":"Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation.","date":"1999","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/10233167","citation_count":155,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15772310","id":"PMC_15772310","title":"Evolution of distinct EGF domains with specific functions.","date":"2005","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/15772310","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19073827","id":"PMC_19073827","title":"EGF increases TRPM6 activity and surface expression.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19073827","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2868013","id":"PMC_2868013","title":"Localization of the epidermal growth factor (EGF) receptor within the endosome of EGF-stimulated epidermoid carcinoma (A431) cells.","date":"1986","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/2868013","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9619445","id":"PMC_9619445","title":"Activation of EGF receptor by oxidized LDL.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9619445","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2164634","id":"PMC_2164634","title":"Evidence for epidermal growth factor (EGF)-induced intermolecular autophosphorylation of the EGF receptors in living cells.","date":"1990","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/2164634","citation_count":123,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12483525","id":"PMC_12483525","title":"Cisplatin-induced activation of the EGF receptor.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12483525","citation_count":122,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1933488","id":"PMC_1933488","title":"The EGF receptor system as a target for antitumor therapy.","date":"1991","source":"Cancer investigation","url":"https://pubmed.ncbi.nlm.nih.gov/1933488","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11956311","id":"PMC_11956311","title":"Role of Grb2 in EGF-stimulated EGFR internalization.","date":"2002","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11956311","citation_count":115,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8089657","id":"PMC_8089657","title":"FGF and EGF are mitogens for immortalized neural progenitors.","date":"1994","source":"Journal of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/8089657","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9099730","id":"PMC_9099730","title":"Divergence in signal transduction pathways of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors. Involvement of sphingosine 1-phosphate in PDGF but not EGF signaling.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9099730","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3030297","id":"PMC_3030297","title":"Epidermal growth factor (EGF) stimulates inositol trisphosphate formation in cells which overexpress the EGF receptor.","date":"1987","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3030297","citation_count":107,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12099696","id":"PMC_12099696","title":"Helicobacter pylori-stimulated EGF receptor transactivation requires metalloprotease cleavage of HB-EGF.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/12099696","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10764734","id":"PMC_10764734","title":"Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10764734","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8396328","id":"PMC_8396328","title":"Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts.","date":"1993","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8396328","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1556153","id":"PMC_1556153","title":"Kinetics of binding, endocytosis, and recycling of EGF receptor mutants.","date":"1992","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/1556153","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10499427","id":"PMC_10499427","title":"Entry of EGF into brain is rapid and saturable.","date":"1999","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/10499427","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10648233","id":"PMC_10648233","title":"Drosophila bunched integrates opposing DPP and EGF signals to set the operculum boundary.","date":"2000","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10648233","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21349850","id":"PMC_21349850","title":"MAPK scaffold IQGAP1 binds the EGF receptor and modulates its activation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21349850","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16953218","id":"PMC_16953218","title":"EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16953218","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19336395","id":"PMC_19336395","title":"The intracellular juxtamembrane domain of the epidermal growth factor (EGF) receptor is responsible for the allosteric regulation of EGF binding.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19336395","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22416276","id":"PMC_22416276","title":"Regulation of the EGF transcriptional response by endocytic sorting.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22416276","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1939154","id":"PMC_1939154","title":"Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1939154","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8416997","id":"PMC_8416997","title":"Consumption of EGF by A431 cells: evidence for receptor recycling.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8416997","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2824387","id":"PMC_2824387","title":"Stimulation by EGF of the growth of EGF receptor-hyperproducing tumor cells in athymic mice.","date":"1987","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/2824387","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2002633","id":"PMC_2002633","title":"Epidermal growth factor (EGF) expression in the congenital polycystic mouse kidney.","date":"1991","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/2002633","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3168791","id":"PMC_3168791","title":"Retinoic acid alters EGF receptor expression during palatogenesis.","date":"1988","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/3168791","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1420877","id":"PMC_1420877","title":"Implications of epidermal growth factor (EGF) induced egf receptor aggregation.","date":"1992","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1420877","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12919676","id":"PMC_12919676","title":"CAML is required for efficient EGF receptor recycling.","date":"2003","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/12919676","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15010282","id":"PMC_15010282","title":"Mitochondrial ROS generation following acetylcholine-induced EGF receptor transactivation requires metalloproteinase cleavage of proHB-EGF.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/15010282","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9698526","id":"PMC_9698526","title":"The EGF\\EGF-receptor axis modulates enterocyte apoptosis during intestinal adaptation.","date":"1998","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/9698526","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16984407","id":"PMC_16984407","title":"EGF-induced activation of the EGF receptor does not trigger mobilization of caveolae.","date":"2006","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/16984407","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1934026","id":"PMC_1934026","title":"Immunoreactivities for epidermal growth factor (EGF) and for EGF receptors in rats with gastric ulcers.","date":"1991","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/1934026","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10331974","id":"PMC_10331974","title":"Hedgehog activates the EGF receptor pathway during Drosophila head development.","date":"1999","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/10331974","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9729715","id":"PMC_9729715","title":"Complexity of EGF receptor signalling revealed in Drosophila.","date":"1998","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/9729715","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9531530","id":"PMC_9531530","title":"EGF domain swap converts a drosophila EGF receptor activator into an inhibitor.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9531530","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6264233","id":"PMC_6264233","title":"Controlled proteolysis of EGF receptors: evidence for transmembrane distribution of the EGF binding and phosphate acceptor sites.","date":"1980","source":"Journal of supramolecular structure","url":"https://pubmed.ncbi.nlm.nih.gov/6264233","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11865189","id":"PMC_11865189","title":"EGF receptor transactivation mediated by the proteolytic production of EGF-like agonists.","date":"2000","source":"Science's STKE : signal transduction knowledge environment","url":"https://pubmed.ncbi.nlm.nih.gov/11865189","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3260374","id":"PMC_3260374","title":"A novel effect of EGF on mRNA stability.","date":"1988","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3260374","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9202048","id":"PMC_9202048","title":"Coupling of epidermal growth factor (EGF) with the antiproliferative activity of cAMP induces neuronal differentiation.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9202048","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9056652","id":"PMC_9056652","title":"Epithelial induction in dermatofibroma: a role for the epidermal growth factor (EGF) receptor.","date":"1997","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/9056652","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15579470","id":"PMC_15579470","title":"Srcasm modulates EGF and Src-kinase signaling in keratinocytes.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15579470","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10441488","id":"PMC_10441488","title":"Spatial organization of EGF receptor transmodulation by PDGF.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10441488","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7819590","id":"PMC_7819590","title":"Targeting the EGF receptor in breast cancer treatment.","date":"1994","source":"Breast cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/7819590","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15373782","id":"PMC_15373782","title":"Epidermal growth factor gene (EGF) polymorphism and risk of melanocytic neoplasia.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15373782","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20211660","id":"PMC_20211660","title":"Colocalization of mineralocorticoid and EGF receptor at the plasma membrane.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20211660","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27932973","id":"PMC_27932973","title":"Decline in Proliferation and Immature Neuron Markers in the Human Subependymal Zone during Aging: Relationship to EGF- and FGF-Related Transcripts.","date":"2016","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27932973","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9642213","id":"PMC_9642213","title":"High-affinity binding of epidermal growth factor (EGF) to EGF receptor is disrupted by overexpression of mutant dynamin (K44A).","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9642213","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11181057","id":"PMC_11181057","title":"EGF family ligand-dependent phenotypic modulation of smooth muscle cells through EGF receptor.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11181057","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11350072","id":"PMC_11350072","title":"Identification of serum factor inducing ectodomain shedding of proHB-EGF and sStudies of noncleavable mutants of proHB-EGF.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11350072","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1847336","id":"PMC_1847336","title":"EGF- and PDGF-stimulated phosphorylation in young and senescent WI-38 cells.","date":"1991","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/1847336","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18764928","id":"PMC_18764928","title":"ARAP1 regulates EGF receptor trafficking and signalling.","date":"2008","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/18764928","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12952932","id":"PMC_12952932","title":"Local signaling by the EGF receptor.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12952932","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8242852","id":"PMC_8242852","title":"Phosphatase inhibitors, gap junctional intercellular communication and [125I]-EGF binding in hamster fibroblasts.","date":"1993","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8242852","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15634742","id":"PMC_15634742","title":"A role for ERK1/2 in EGF- and ATP-dependent regulation of amiloride-sensitive sodium absorption.","date":"2005","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634742","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23246849","id":"PMC_23246849","title":"Disruption of the annexin A1/S100A11 complex increases the migration and clonogenic growth by dysregulating epithelial growth factor (EGF) signaling.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/23246849","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27788212","id":"PMC_27788212","title":"EGF Functionalized Polymer-Coated Gold Nanoparticles Promote EGF Photostability and EGFR Internalization for Photothermal Therapy.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27788212","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25479591","id":"PMC_25479591","title":"EGF stimulates the activation of EGF receptors and the selective activation of major signaling pathways during mitosis.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25479591","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17462600","id":"PMC_17462600","title":"Involvement of Rabring7 in EGF receptor degradation as an E3 ligase.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17462600","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18083120","id":"PMC_18083120","title":"Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18083120","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"233024","id":"PMC_233024","title":"Hormone-induced modification of EGF receptor proteolysis in the induction of EGF action.","date":"1979","source":"Journal of supramolecular structure","url":"https://pubmed.ncbi.nlm.nih.gov/233024","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33101846","id":"PMC_33101846","title":"EGF Relays Signals to COP1 and Facilitates FOXO4 Degradation to Promote Tumorigenesis.","date":"2020","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/33101846","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11795531","id":"PMC_11795531","title":"Attenuation of EGF signaling in senescent cells by caveolin.","date":"2001","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11795531","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9787980","id":"PMC_9787980","title":"Role of epidermal growth factor (EGF) in oesophageal mucosal integrity.","date":"1998","source":"Current medical research and opinion","url":"https://pubmed.ncbi.nlm.nih.gov/9787980","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15838103","id":"PMC_15838103","title":"Origins of growth factors: NGF and EGF.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15838103","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17626784","id":"PMC_17626784","title":"SNP analyses of growth factor genes EGF, TGFbeta-1, and HGF reveal haplotypic association of EGF with autism.","date":"2007","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/17626784","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19798056","id":"PMC_19798056","title":"Participation of Tom1L1 in EGF-stimulated endocytosis of EGF receptor.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19798056","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6332542","id":"PMC_6332542","title":"Transport of 125I-EGF into milk and effect of sialoadenectomy on milk EGF in mice.","date":"1984","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/6332542","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8927309","id":"PMC_8927309","title":"Human lens epithelial cells proliferate in response to exogenous EGF and have EGF and EGF receptor.","date":"1995","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/8927309","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7673217","id":"PMC_7673217","title":"A single amino acid exchange, Arg-45 to Ala, generates an epidermal growth factor (EGF) mutant with high affinity for the chicken EGF receptor.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7673217","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8732299","id":"PMC_8732299","title":"Epidermal growth factor (EGF).","date":"1996","source":"Bailliere's clinical gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/8732299","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1727483","id":"PMC_1727483","title":"Evidence for intracellular down-regulation of the epidermal growth factor (EGF) receptor during adenovirus infection by an EGF-independent mechanism.","date":"1992","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/1727483","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19022560","id":"PMC_19022560","title":"NM23H2 inhibits EGF- and Ras-induced proliferation of NIH3T3 cells by blocking the ERK pathway.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/19022560","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9665807","id":"PMC_9665807","title":"Suppression of ruffling by the EGF receptor in chemotactic cells.","date":"1998","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/9665807","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2475671","id":"PMC_2475671","title":"Epidermal growth factor (EGF) prevents methylprednisolone-induced inhibition of wound healing.","date":"1989","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/2475671","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12606820","id":"PMC_12606820","title":"Modulation of trophoblast cell death by oxygen and EGF.","date":"2002","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/12606820","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22531034","id":"PMC_22531034","title":"Regulated intramembrane cleavage of the EGF receptor.","date":"2012","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/22531034","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6322847","id":"PMC_6322847","title":"Epidermal growth factor (EGF) binding to membranes immobilized in microtiter wells and estimation of EGF-related transforming growth factor activity.","date":"1984","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/6322847","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10918615","id":"PMC_10918615","title":"Evidence that Argos is an antagonistic ligand of the EGF receptor.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10918615","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23658295","id":"PMC_23658295","title":"Deja Vu: EGF receptors drive resistance to BRAF inhibitors.","date":"2013","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/23658295","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21059162","id":"PMC_21059162","title":"Regulation of EGF-stimulated EGF receptor endocytosis during M phase.","date":"2010","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/21059162","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31537645","id":"PMC_31537645","title":"Epidermal growth factor (EGF) triggers nuclear calcium signaling through the intranuclear phospholipase Cδ-4 (PLCδ4).","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31537645","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7835273","id":"PMC_7835273","title":"Epidermal growth factor (EGF) receptor carboxy-terminal domains are required for EGF-induced glucose transport in transgenic 3T3-L1 adipocytes.","date":"1995","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/7835273","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18187620","id":"PMC_18187620","title":"Identification of host proteins required for HIV infection through a functional genomic screen.","date":"2008","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18187620","citation_count":1165,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12297050","id":"PMC_12297050","title":"Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12297050","citation_count":941,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15837620","id":"PMC_15837620","title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.","date":"2005","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15837620","citation_count":887,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17349580","id":"PMC_17349580","title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.","date":"2007","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/17349580","citation_count":878,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9687510","id":"PMC_9687510","title":"Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.","date":"1998","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9687510","citation_count":842,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18583979","id":"PMC_18583979","title":"Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database.","date":"2008","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18583979","citation_count":817,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12620237","id":"PMC_12620237","title":"EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/12620237","citation_count":614,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11786904","id":"PMC_11786904","title":"Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11786904","citation_count":606,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11894095","id":"PMC_11894095","title":"Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/11894095","citation_count":471,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15950906","id":"PMC_15950906","title":"Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway.","date":"2005","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15950906","citation_count":435,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"6603475","id":"PMC_6603475","title":"Human plasma epidermal growth factor/beta-urogastrone is associated with blood platelets.","date":"1983","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/6603475","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9020193","id":"PMC_9020193","title":"Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9020193","citation_count":428,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10436156","id":"PMC_10436156","title":"Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3.","date":"1999","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10436156","citation_count":406,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2790960","id":"PMC_2790960","title":"Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2790960","citation_count":369,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3491360","id":"PMC_3491360","title":"Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization.","date":"1986","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/3491360","citation_count":349,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7736574","id":"PMC_7736574","title":"Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7736574","citation_count":346,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1372091","id":"PMC_1372091","title":"Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors.","date":"1992","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/1372091","citation_count":331,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9135143","id":"PMC_9135143","title":"Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9135143","citation_count":309,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28988771","id":"PMC_28988771","title":"EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.","date":"2017","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/28988771","citation_count":300,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23382691","id":"PMC_23382691","title":"Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers.","date":"2013","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23382691","citation_count":292,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10648629","id":"PMC_10648629","title":"A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10648629","citation_count":291,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15802268","id":"PMC_15802268","title":"Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15802268","citation_count":277,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7640657","id":"PMC_7640657","title":"The epidermal growth factor.","date":"1995","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/7640657","citation_count":263,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14560030","id":"PMC_14560030","title":"Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14560030","citation_count":257,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44365,"output_tokens":8115,"usd":0.12741},"stage2":{"model":"claude-opus-4-6","input_tokens":11915,"output_tokens":4136,"usd":0.244462},"total_usd":0.865453,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":57979,"output_tokens":13443,"usd":0.187791},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":17737,"output_tokens":4607,"usd":0.30579}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"EGF binding to its receptor stimulates rapid tyrosine phosphorylation of phospholipase C-II (PLC-II); PLC-II co-immunoprecipitates with the EGF receptor, indicating direct association; this phosphorylation links EGFR tyrosine kinase activity to PIP2 hydrolysis and Ca2+ release.\",\n      \"method\": \"Immunoblotting with phosphotyrosine-specific antibodies, co-immunoprecipitation, pharmacological inhibition of tyrosine kinase\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus functional pharmacological validation in multiple cell types\",\n      \"pmids\": [\"2472218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1980,\n      \"finding\": \"The EGF binding site resides on the extracellular face of the membrane and the phosphate acceptor (kinase) site resides on the cytoplasmic face, demonstrating transmembrane topology of the EGF receptor with intrinsic kinase on the intracellular side.\",\n      \"method\": \"Controlled proteolysis of A431 cell membranes, direct EGF crosslinking, 32Pi phosphorylation with lysolecithin permeabilization\",\n      \"journal\": \"Journal of supramolecular structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with membrane fractionation and covalent crosslinking; foundational topology paper\",\n      \"pmids\": [\"6264233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"EGF receptor autophosphorylation occurs by intermolecular (trans) cross-phosphorylation between receptor molecules in living cells; a kinase-negative mutant (K721A) is phosphorylated by co-expressed active receptor upon EGF stimulation, and the kinase-negative mutant acts as a dominant-negative suppressor of mitogenic signaling.\",\n      \"method\": \"Co-expression of kinase-dead and active EGFR mutants in transfected cells, immunoprecipitation, dominant-negative analysis of mitogenic response\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — active-site mutagenesis with functional rescue and dominant-negative validation\",\n      \"pmids\": [\"2164634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The purified EGF receptor directly binds F-actin via an actin-binding domain corresponding to amino acid residues 984–996 of the intracellular domain (homologous to the actin-binding domain of Acanthamoeba profilin); a synthetic peptide (HL-33) corresponding to this region competes with EGFR for actin binding.\",\n      \"method\": \"Cosedimentation of purified EGFR with purified F-actin, competition with synthetic peptides and polyclonal antibody, truncation mutant control\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified proteins and peptide competition mapping\",\n      \"pmids\": [\"1383230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"EGF stimulates EGF receptor synthesis by increasing EGFR mRNA levels 3–5 fold, counterbalancing ligand-induced receptor degradation; this effect is at the level of mRNA accumulation.\",\n      \"method\": \"Biosynthetic 35S-methionine labeling + immunoprecipitation, Northern blot with EGFR cDNA probes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (metabolic labeling + Northern blot) in same study\",\n      \"pmids\": [\"2420792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"EGF greatly prolongs the half-life of EGF receptor mRNA (mRNA stabilization), providing a mechanism for EGF-stimulated increases in EGFR mRNA levels; EGF also stabilizes beta-tubulin and beta-actin mRNAs.\",\n      \"method\": \"mRNA decay assay after actinomycin D addition; comparison with PMA treatment\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean mRNA stability assay, single lab, single method\",\n      \"pmids\": [\"3260374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"Upon EGF stimulation, the EGF-receptor complex is internalized into a peripheral endosomal network and subsequently transported to a pericentriolar multivesicular body compartment before lysosomal degradation; transfer to lysosomes is a temperature-dependent, discontinuous step.\",\n      \"method\": \"HRP-EGF conjugate electron microscopy, anti-receptor antibody gold immunocytochemistry, acid phosphatase cytochemistry, temperature-shift experiments in A431 cells\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization with multiple EM-based orthogonal approaches and functional temperature-shift controls\",\n      \"pmids\": [\"2868013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"EGF stimulates rapid inositol 1,4,5-trisphosphate (Ins-1,4,5-P3) formation and PIP2 hydrolysis in cells overexpressing the EGF receptor (A431 cells and five other receptor-overexpressing lines), linking EGFR activation to the phosphoinositide second messenger pathway.\",\n      \"method\": \"Inositol phosphate biochemical assay, PIP2 lipid measurement in multiple cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — replicated across six cell lines, single lab\",\n      \"pmids\": [\"3030297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Sustained and pronounced nuclear translocation of p42/p44 MAP kinase in response to EGF (achieved by EGFR overexpression in PC12 cells) is sufficient to trigger neuronal differentiation, indicating that the duration and nuclear localization of MAP kinase activation, not a pathway specific to NGF, determines the differentiation outcome.\",\n      \"method\": \"Overexpression of wild-type and mutant EGFR in PC12 cells, MAP kinase activity assays, immunofluorescence for nuclear translocation, morphological differentiation readout\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via receptor overexpression/mutation with multiple orthogonal readouts (kinase activity + localization + differentiation)\",\n      \"pmids\": [\"7953555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ErbB2/ErbB4 heterodimers bind all EGF family ligands with moderate to very high affinity; ErbB3 shows restricted ligand binding; ErbB2 preferentially enhances ligand binding to ErbB3 or ErbB4, establishing binding specificity rules for ErbB receptor combinations.\",\n      \"method\": \"Soluble receptor-ligand binding assay with defined ErbB receptor combinations, quantitative binding affinity measurements for 11 EGF-domain ligands\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic in vitro reconstitution with defined receptor combinations and quantitative affinity measurements\",\n      \"pmids\": [\"10214951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EGFR-ErbB2 heterodimerization (driven by ErbB2 overexpression) impairs EGF-induced EGFR endocytosis; ErbB2 itself is not endocytosed in response to EGF; the endocytosis deficiency maps to the intracellular domain of ErbB2, as a chimera with ErbB2 ectodomain/EGFR intracellular domain undergoes normal endocytosis.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation, Western blotting, indirect immunofluorescence, microinjection of ErbB2 expression plasmid, chimeric receptor domain-swap experiment\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods plus domain-swap chimera; replicated across four cell lines\",\n      \"pmids\": [\"10233167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Grb2 is recruited from cytoplasm to plasma membrane within 1 minute of EGF stimulation via SH2-dependent binding to EGFR; Grb2 and EGFR co-internalize via a macropinocytic, clathrin-independent pathway; the Grb2 SH3 domain couples EGFR-containing membranes to downstream effectors required for internalization.\",\n      \"method\": \"Live-cell imaging of GFP-tagged Grb2 and EGFR, SH2/SH3 domain mutant analysis, AP-180 C-terminus clathrin inhibition, transferrin as clathrin-dependent control\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live imaging plus domain mutagenesis plus orthogonal clathrin inhibition controls\",\n      \"pmids\": [\"11956311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Decorin binds to the EGFR L2 ligand-binding domain at residues His394–Ile402, partially overlapping but distinct from the EGF binding site (K465 is required for EGF but not decorin binding); this interaction antagonizes EGFR tyrosine kinase activity.\",\n      \"method\": \"Decorin/alkaline phosphatase chimera expression cloning, yeast two-hybrid, EGF competition assay, EGFR deletion mutants, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal binding assays plus site-directed mutagenesis identifying specific residues\",\n      \"pmids\": [\"12105206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MMP-generated laminin-5 domain III (DIII) fragment binds to EGFR and stimulates downstream MAP kinase signaling, MMP-2 gene expression, and cell migration, establishing that an ECM-derived EGF-like fragment can directly activate EGFR as a cryptic ligand.\",\n      \"method\": \"Recombinant DIII fragment binding to EGFR, MAPK signaling assay, MMP-2 gene expression, cell migration assay, TIMP-3 KO mouse tissue validation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — recombinant protein binding with functional downstream readouts and in vivo genetic validation\",\n      \"pmids\": [\"12695504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cisplatin activates EGFR in a ligand-independent manner; this requires EGFR kinase activity and is mediated by c-Src kinases (blocked by Src-family inhibitor PP1 and by kinase-dead receptor); EGFR activation by cisplatin promotes cell survival.\",\n      \"method\": \"EGFR phosphorylation assays, kinase-dead receptor expression, Src kinase inhibitor PP1, EGFR kinase inhibitor, cell viability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological and genetic (kinase-dead) epistasis with functional survival readout\",\n      \"pmids\": [\"12483525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CALCIUM-MODULATING CYCLOPHILIN LIGAND (CAML) directly associates with the EGFR kinase domain in a ligand-dependent manner and is required for efficient recycling of internalized EGFR to the plasma membrane; CAML-deficient cells show normal EGF-induced signaling and internalization but impaired receptor recycling and reduced proliferative response.\",\n      \"method\": \"CAML gene knockout in mice, co-immunoprecipitation demonstrating direct EGFR-CAML interaction, subcellular fractionation, receptor recycling assays, proliferation assays\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple orthogonal mechanistic assays\",\n      \"pmids\": [\"12919676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"GM3 ganglioside inhibits EGFR autophosphorylation (kinase domain activation) in a reconstituted proteoliposome system; inhibition requires membrane phase separation into coexisting liquid domains and depends on a membrane-proximal lysine (K642) of EGFR; GM3 prevents the allosteric transition from inactive to active EGFR dimer.\",\n      \"method\": \"Reconstitution of human EGFR into proteoliposomes of defined lipid composition, autophosphorylation kinase assay, neuraminidase treatment, K642G site-directed mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with defined lipids plus mutagenesis; minimal synthetic system\",\n      \"pmids\": [\"21571640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IQGAP1 directly binds EGFR through its IQ domain (IQGAP1) and kinase domain (EGFR); IQGAP1 is required for full EGF-induced EGFR autophosphorylation; calmodulin disrupts IQGAP1-EGFR interaction; EGF induces PKCα-dependent phosphorylation of IQGAP1 Ser1443 via EGFR.\",\n      \"method\": \"Co-immunoprecipitation of endogenous proteins, in vitro direct binding assay, mass spectrometry phosphorylation mapping, IQGAP1-null cell reconstitution, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro binding plus MS site identification plus KO reconstitution with multiple mutants\",\n      \"pmids\": [\"21349850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Molecular dynamics simulations show that ligand-bound EGFR dimers adopt N-terminal transmembrane helix dimerization, juxtamembrane segment dimerization, and asymmetric (active) kinase dimer conformation; ligand-free dimers adopt C-terminal TM dimerization, JM dissociation/membrane burial, and symmetric (inactive) kinase dimers; electrostatic interactions of the intracellular module with the membrane are critical for this coupling.\",\n      \"method\": \"Molecular dynamics simulations of membrane-embedded full-length EGFR dimers\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 structural/computational — highly detailed, published in Cell, but computationally only without crystal/cryo-EM validation within the same study\",\n      \"pmids\": [\"23374350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The intracellular juxtamembrane domain of EGFR is required for both negative cooperativity in EGF binding and positive linkage between ligand binding and receptor dimerization; autophosphorylation of the receptor abolishes the positive linkage between EGF binding and dimerization, demonstrating inside-out signaling.\",\n      \"method\": \"EGF binding analysis to multiple EGFR mutants (juxtamembrane deletions, phosphorylation-site mutants), mathematical modeling of cooperativity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis with quantitative binding analysis revealing domain function\",\n      \"pmids\": [\"19336395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Somatic EGFR kinase domain mutations found in gefitinib-sensitive NSCLC cause EGF-independent (constitutive) EGFR tyrosine phosphorylation and cell mitogenesis; mutations disrupt the autoinhibitory interaction between the activation loop and αC helix of the inactive kinase domain.\",\n      \"method\": \"Expression of mutant EGFRs in null-background cells, EGF-independent phosphorylation and Ba/F3 mitogenesis assays, structural analysis of autoinhibitory interactions\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — biochemical characterization of multiple mutants with structural mechanistic interpretation\",\n      \"pmids\": [\"16953218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"H. pylori stimulates EGFR transactivation through induction of HB-EGF gene expression and metalloprotease-dependent cleavage/release of surface HB-EGF (the 'triple membrane passing signal'); this transactivation requires metalloprotease, EGFR, and MEK1 activities and mediates IL-8 release.\",\n      \"method\": \"HB-EGF gene expression analysis, EGFR tyrosine phosphorylation assays, metalloprotease inhibitors, MEK1 inhibitors, requirement for surface proHB-EGF\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with multiple pathway inhibitors establishing pathway order\",\n      \"pmids\": [\"12099696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EGF-induced stimulation of TRPM6 Mg2+ channel activity occurs via EGFR → Src family kinases → Rac1 signaling; Rac1 increases TRPM6 membrane mobility (FRAP) and surface abundance; dominant-negative Rac1 abolishes EGF-mediated TRPM6 activation.\",\n      \"method\": \"Whole-cell patch-clamp, FRAP, constitutively active and dominant-negative Rac1 constructs, Src kinase inhibitors, pharmacological dissection of pathway\",\n      \"journal\": \"Journal of the American Society of Nephrology : JASN\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiology plus FRAP plus genetic epistasis with multiple orthogonal approaches\",\n      \"pmids\": [\"19073827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Rabring7 functions as an E3 ubiquitin ligase (via its RING finger domain, with Ubc4/Ubc5 as preferred E2 partners) and accelerates ligand-induced EGFR degradation; a RING-finger mutant (C229S) lacking E3 activity inhibits cCbl-induced EGFR degradation, placing Rabring7 in the endocytic trafficking pathway for EGFR.\",\n      \"method\": \"In vitro ubiquitination assay with recombinant E1 and E2 proteins, RING-finger point mutagenesis, EGFR degradation assay in cells\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of E3 ligase activity plus mutagenesis plus cellular degradation assay\",\n      \"pmids\": [\"17462600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tom1L1 is transiently tyrosine-phosphorylated by Src family kinases upon EGF stimulation, enabling it to associate with activated EGFR via a Grb2/Shc bridge; Tom1L1 is recruited to the plasma membrane and then to early endosomes; its C-terminal clathrin-interacting motif engages clathrin heavy chain to couple EGFR to the endocytic machinery; Tom1L1 knockdown or dominant-negative mutants inhibit EGFR endocytosis.\",\n      \"method\": \"Co-immunoprecipitation, RNAi knockdown, dominant-negative mutant analysis, clathrin interaction mapping, phosphorylation site mutagenesis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus RNAi plus domain mapping with multiple mutants\",\n      \"pmids\": [\"19798056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The EGF transcriptional response is primarily elicited by EGFR at the cell surface; retaining activated EGFR at the cell surface (by blocking ubiquitination or endocytosis) amplifies many EGF-induced transcripts, whereas blocking EGFR sorting into intraluminal vesicles (ESCRT depletion) increases kinase activation but has little effect on transcript profiles.\",\n      \"method\": \"ESCRT depletion by siRNA, receptor endocytosis/ubiquitination blockade, transcriptome profiling, kinase activation assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis (RNAi) with orthogonal interventions and transcriptome readout\",\n      \"pmids\": [\"22416276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EGF-induced EGFR trafficking to lysosomes requires the annexin A1/S100A11 complex; annexin A1 is phosphorylated by internalized EGFR on endosomes and facilitates inward vesiculation in multivesicular bodies; loss of S100A11 or the annexin A1 N-terminal interaction domain delays EGFR transport and prolongs MAP kinase signaling.\",\n      \"method\": \"Dominant-negative annexin A1 N-terminal truncation mutant, S100A11 siRNA depletion, EGFR trafficking assays to LAMP1+ compartments, EGFR degradation assays, MAP kinase signaling time course\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic and dominant-negative approaches with multiple orthogonal trafficking and signaling readouts\",\n      \"pmids\": [\"23246849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"EGF or ionomycin stimulation triggers rhomboid intramembrane protease-mediated cleavage of EGFR, producing a ~60 kDa intracellular domain fragment found in membrane and nuclear fractions; γ-secretase is not responsible; calpain inhibition increases detectable ICD fragment levels.\",\n      \"method\": \"Chemical inhibitor profiling, rhomboid and γ-secretase protease cDNA overexpression, Western blot of subcellular fractions in A431 cells\",\n      \"journal\": \"Traffic (Copenhagen, Denmark)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological plus cDNA overexpression evidence; single lab\",\n      \"pmids\": [\"22531034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Nuclear-translocated EGFR triggers Ca2+ release from the nucleoplasmic reticulum via hydrolysis of nuclear PI(4,5)P2 by intranuclear PLCδ4 (not PLCγ1), generating InsP3; nuclear PKC is activated downstream; PLCδ4 and InsP3 modulate cell cycle progression by regulating cyclin A and B1 expression.\",\n      \"method\": \"Subcellular fractionation, siRNA knockdown of PLCδ4, FRET-based Ca2+ biosensors, nuclear InsP3 buffering, EGFR nuclear translocation inhibition, cyclin expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches (RNAi, FRET biosensors, pharmacological, nuclear buffering) in same study\",\n      \"pmids\": [\"31537645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Oxidized LDL (oxLDL) and its lipid peroxidation product 4-hydroxynonenal (4-HNE) activate EGFR through direct chemical derivatization of the receptor, independent of EGF ligand; immunopurified EGFR is derivatized and activated in vitro by oxLDL lipid extracts and 4-HNE.\",\n      \"method\": \"In vitro activation of immunopurified EGFR by oxLDL lipid extracts and 4-HNE, EGFR tyrosine phosphorylation assay, cellular signaling pathway analysis\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assay with purified receptor, but single lab and limited mechanistic depth\",\n      \"pmids\": [\"9619445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Arg-45 in human EGF is a key determinant for receptor binding specificity: replacing Arg-45 with Ala (the corresponding residue in TGFα) is sufficient to confer high affinity binding to the chicken EGF receptor, demonstrating the critical role of this residue in the EGF–receptor interface.\",\n      \"method\": \"Domain-exchange chimeras and point mutants of hEGF/hTGFα, competitive binding assays on chicken EGF receptor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis with quantitative binding assays identifying single critical residue\",\n      \"pmids\": [\"7673217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"EGF receptor internalization rate is stimulated ~50-fold at saturating EGF concentrations; high-affinity EGF binding results from increased apparent on-rate; tyrosine kinase activity and the Thr654 region (PKC phosphorylation site) are required for the enhanced internalization at low EGF concentrations.\",\n      \"method\": \"EGF receptor internalization kinetics assays, phorbol ester treatment, kinase-dead (K721A) and Thr654 point mutant receptors, mAb108 competition\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis with kinetic internalization assays across multiple conditions\",\n      \"pmids\": [\"1556153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EGF signaling promotes FOXO4 ubiquitin-mediated degradation via a CSN6–COP1 axis: EGF elevates CSN6 levels, which binds FOXO4 and enhances COP1 E3 ligase activity; COP1 directly interacts with FOXO4 through a VP motif on FOXO4 to accelerate its ubiquitin-mediated proteolysis, suppressing SGOC metabolic gene expression.\",\n      \"method\": \"Co-immunoprecipitation of CSN6-FOXO4 and COP1-FOXO4, ubiquitination assays, VP-motif mutagenesis, FOXO4 promoter binding assays, metabolomics\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus ubiquitination assay plus motif mutagenesis; single lab\",\n      \"pmids\": [\"33101846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"EGF-induced glucose transport (GLUT4 translocation to plasma membrane) in adipocytes expressing EGFR requires the EGFR carboxy-terminal autophosphorylation domain; a truncated EGFR (c'973, lacking all autophosphorylation motifs) fails to stimulate glucose transport despite activating MAP kinase, indicating that autophosphorylation sites couple EGFR to the glucose transport pathway.\",\n      \"method\": \"Retroviral transduction of full-length vs. truncated EGFR in 3T3-L1 adipocytes, glucose transport assay, GLUT4 translocation by subcellular fractionation, receptor autophosphorylation assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — domain truncation mutagenesis with functional glucose transport and GLUT4 translocation readouts\",\n      \"pmids\": [\"7835273\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EGF binds the extracellular domain of its receptor (EGFR), inducing receptor dimerization and intermolecular trans-autophosphorylation of the intracellular tyrosine kinase domain; the activated receptor recruits and phosphorylates substrates including PLCγ (triggering PIP2 hydrolysis, IP3 generation, and Ca2+ release), engages adaptor proteins (Grb2, Shc, Tom1L1) to initiate clathrin-mediated endocytosis, undergoes rhomboid-mediated intramembrane cleavage releasing a nuclear ICD that activates nuclear PLCδ4 for nuclear Ca2+ signaling, and is subject to feedback regulation through GM3-mediated lipid inhibition of kinase activation, PKC-dependent Thr654 phosphorylation, EGFR mRNA stabilization, and ubiquitin-mediated lysosomal degradation facilitated by Rabring7 and the annexin A1/S100A11 complex in multivesicular bodies.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\nKey exclusions:\n- Papers 9 (Nimrod/Drosophila phagocytosis receptor - not EGF ortholog, different protein entirely)\n- Papers about non-EGF genes that happen to mention EGF signaling peripherally\n- Additional curated papers: 1,2,6,7,8,9,11,14,18,26 (cDNA libraries, HIV screen, MSK1, schizophrenia genetics, GO consortium, IgG glycosylation) - these are not about EGF mechanistically\n- Papers focused purely on expression/prognosis without mechanism\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"EGF binding to EGFR triggers tyrosine phosphorylation of phospholipase C-II (PLCγ), which co-immunoprecipitates with the EGF receptor; this phosphorylation links EGFR tyrosine kinase activity to PIP2 hydrolysis and EGF-induced Ca2+ release. Tyrphostin kinase inhibitor blocks both PLC-II phosphorylation and its association with EGFR.\",\n      \"method\": \"Co-immunoprecipitation, phosphotyrosine immunoblotting, kinase inhibitor experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with functional validation (Ca2+ release blocked by kinase inhibitor), highly cited\",\n      \"pmids\": [\"2472218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1980,\n      \"finding\": \"The EGF binding site of the EGFR is on the extracellular (external) face of the plasma membrane, while the phosphate acceptor (kinase substrate) site is on the cytoplasmic face, demonstrating the transmembrane topology of the receptor and that EGF-stimulated phosphorylation requires cell permeabilization for ATP access.\",\n      \"method\": \"Controlled proteolysis of intact vs. permeabilized cells, direct linkage cross-linking, 32P-ATP labeling with lysolecithin permeabilization\",\n      \"journal\": \"Journal of supramolecular structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical reconstitution with direct experimental demonstration of transmembrane orientation\",\n      \"pmids\": [\"6264233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"EGF stimulates its own receptor synthesis: EGF treatment of WB hepatic cells increased EGFR mRNA levels 3–5-fold and stimulated new receptor protein synthesis within 2 hours, providing a positive feedback mechanism that counterbalances ligand-induced receptor degradation.\",\n      \"method\": \"Biosynthetic [35S]methionine labeling with immunoprecipitation, Northern blot with EGFR cDNA probes\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — two orthogonal methods (metabolic labeling + Northern blot) in a single study\",\n      \"pmids\": [\"2420792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"EGF and its receptor localize together within endosomal compartments (peripheral branching tubular network and pericentriolar multivesicular bodies) following EGF stimulation; the EGF-receptor complex redistributes from peripheral to pericentriolar endosomes in a temperature-dependent step before entering lysosomes.\",\n      \"method\": \"Immunoelectron microscopy with HRP-EGF and anti-receptor antibody-gold on A431 cells, frozen thin sections\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization by electron microscopy with functional temperature-dependence experiments\",\n      \"pmids\": [\"2868013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The human EGF precursor is a 1,207 amino acid transmembrane protein with EGF flanked by large N- and C-terminal segments; it is expressed as a membrane protein with its N-terminus external to the cell surface, and its gene spans ~110 kb with 24 exons, suggesting exon duplication and shuffling in its evolution.\",\n      \"method\": \"cDNA sequencing, COS-7 cell transfection for expression, gene structure analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct cDNA sequencing and expression in transfected cells, foundational structural characterization\",\n      \"pmids\": [\"3491360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Overexpression of the EGFR in NIH 3T3 cells confers EGF-dependent transformation (focus formation, anchorage-independent growth) without altering basal growth, demonstrating that EGFR overexpression amplifies normal EGF signal transduction and is sufficient to drive oncogenic signaling in the presence of ligand.\",\n      \"method\": \"Eukaryotic expression vector transfection into NIH 3T3 and NR6 cells, focus formation assay, soft agar colony assay, DNA synthesis measurement\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with multiple phenotypic readouts, highly cited foundational paper\",\n      \"pmids\": [\"3500791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"EGF stimulates formation of inositol 1,4,5-trisphosphate (Ins-1,4,5-P3), Ins-1,3,4-P3, and Ins-1,3,4,5-P4, with concurrent decrease in PIP2, in A431 cells overexpressing EGFR and in five other EGFR-overexpressing cell lines, demonstrating EGF-induced activation of the phosphoinositide signaling pathway.\",\n      \"method\": \"Radiolabeled inositol phosphate measurement in multiple cell lines with EGFR overexpression\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — replicated across multiple cell lines in same study\",\n      \"pmids\": [\"3030297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"EGF stabilizes EGF receptor mRNA (prolonging its half-life), as well as β-tubulin and β-actin mRNAs, revealing a novel post-transcriptional mechanism by which EGF upregulates receptor expression distinct from the transcriptional mechanism of phorbol ester (PMA).\",\n      \"method\": \"mRNA decay assay with actinomycin D, Northern blot analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA stability measurement, comparison with PMA mechanism\",\n      \"pmids\": [\"3260374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"A specific 18-amino-acid highly negatively charged C-terminal domain of the EGFR (beyond the kinase domain) is required for EGF-dependent receptor internalization via a high-affinity saturable pathway and for ligand-stimulated cytosolic calcium increases, but kinase-active internalization-defective receptors can still signal gene transcription, morphological transformation, and growth.\",\n      \"method\": \"C-terminal deletion and truncation mutants expressed in cells, internalization assays, calcium measurement, transformation assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple deletion mutants with multiple functional readouts, clearly dissects internalization from signaling domains\",\n      \"pmids\": [\"2790960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"EGF receptor autophosphorylation in living cells occurs by intermolecular cross-phosphorylation (transphosphorylation): a kinase-negative EGFR (K721A mutant) becomes tyrosine phosphorylated by co-expressed active EGFR upon EGF stimulation; the kinase-negative mutant acts as a dominant-negative to suppress mitogenic signaling.\",\n      \"method\": \"Coexpression of kinase-negative and C-terminally truncated active EGFR mutants, EGF-stimulated phosphorylation assay in living cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — elegant genetic epistasis with dominant-negative approach, direct demonstration of trans-phosphorylation\",\n      \"pmids\": [\"2164634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Purified EGFR directly co-sediments with purified F-actin, identifying EGFR as an actin-binding protein. The actin-binding domain maps to amino acids 984–996 (sequence homologous to Acanthamoeba profilin actin-binding domain); a truncated EGFR lacking this region does not co-sediment with actin.\",\n      \"method\": \"Co-sedimentation assay with purified EGFR and F-actin, synthetic peptide competition, polyclonal antibody blocking, direct actin-binding assay with HL-33 peptide\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with purified proteins, domain mapping by peptide competition and antibody blocking\",\n      \"pmids\": [\"1383230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"EGF receptor internalization rate is stimulated ~50-fold at saturating EGF concentrations. High-affinity EGF binding requires the intact cytoplasmic domain; tyrosine kinase activity (Lys721) and the Thr654 region (PKC phosphorylation site) are required for the enhanced internalization of high-affinity receptors at low EGF concentrations.\",\n      \"method\": \"Kinetic binding and internalization assays with EGFR point mutants (K721A, T654A), phorbol ester treatment, blocking antibody experiments\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches with defined mutants and pharmacological tools\",\n      \"pmids\": [\"1556153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"PI 3-kinase p85 subunit associates with activated (autophosphorylated) EGFR via its SH2 domains; either N- or C-terminal SH2 domain of p85 is sufficient for receptor binding; receptor tyrosine autophosphorylation is required for p85 binding; p85 itself is not significantly tyrosine phosphorylated by EGFR, suggesting it acts as an adaptor.\",\n      \"method\": \"Co-immunoprecipitation, GST-SH2 domain pulldown, competitive binding with phosphotyrosine, anti-phosphotyrosine blotting\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding with domain mapping, multiple orthogonal approaches\",\n      \"pmids\": [\"1372091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"EGF receptor recycling occurs multiple times per receptor: A431 cells consume far more EGF molecules than the number of EGFR degraded or down-regulated, with apparent Michaelis-Menten kinetics for EGF consumption; individual EGFR recycle many times, consuming up to 45 EGF molecules per receptor over 6 hours.\",\n      \"method\": \"125I-EGF consumption assay at varying cell densities and EGF concentrations, comparison with receptor down-regulation rates\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative kinetic analysis with rigorous controls\",\n      \"pmids\": [\"8416997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Sustained vs. transient MAP kinase activation determines differentiation vs. proliferation outcome downstream of EGF. Overexpression of EGFR in PC12 cells converts EGF from a mitogen to a differentiation factor by sustaining p42/p44 MAP kinase activity and inducing nuclear translocation of p42 MAP kinase.\",\n      \"method\": \"EGFR overexpression and dominant-negative mutant expression in PC12 cells, MAP kinase activity measurement, nuclear translocation assay, neurite outgrowth measurement\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple EGFR mutants with quantitative kinase activity and differentiation readouts, strong mechanistic dissection\",\n      \"pmids\": [\"7953555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Gβγ subunits of Gi-coupled receptors mediate Src-dependent tyrosine phosphorylation of EGFR (transactivation) without receptor autophosphorylation; this involves Src family kinase recruitment to create phosphotyrosine docking sites for Shc/Grb2, forming a scaffold for Ras activation downstream of GPCRs.\",\n      \"method\": \"Dominant-negative c-Src and Csk expression, anti-phosphotyrosine immunoblotting, autophosphorylation-specific EGFR antibody, GST-Src-SH2 pulldown in COS-7 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including dominant-negative, phosphospecific antibodies, and domain pulldowns\",\n      \"pmids\": [\"9020193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Oxidized LDL activates EGFR tyrosine phosphorylation in intact cells; 4-hydroxynonenal (4-HNE), a lipid peroxidation product, directly derivatizes and activates immunopurified EGFR in vitro, identifying EGFR as a sensor for oxidized lipids and establishing that chemical modification of EGFR can activate its kinase independently of ligand.\",\n      \"method\": \"Anti-phosphotyrosine immunoblotting in intact cells, in vitro kinase activation of immunopurified EGFR with oxLDL lipid extracts and 4-HNE\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — both cell-based and in vitro reconstitution with purified receptor\",\n      \"pmids\": [\"9619445\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EGF receptor binding affinities to ErbB receptor dimers vary dramatically by combination: the ErbB2/4 heterodimer binds all EGF-domain ligands with moderate-to-high affinity, while ErbB3 shows highly restricted binding (only heregulin, neuregulin-2β, epiregulin, and the chimera biregulin); EGF binds ErbB1 but not ErbB4 alone; ErbB2 preferentially enhances ligand binding to ErbB3 or ErbB4.\",\n      \"method\": \"Soluble receptor-ligand binding assay with defined ErbB receptor combinations, competitive binding with EGF-domain proteins\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic quantitative binding in defined reconstituted system with all combinations\",\n      \"pmids\": [\"10214951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EGFR-ErbB2 heterodimerization impairs EGF-induced EGFR endocytosis: in breast cancer cells with high ErbB2/EGFR ratios, EGF-stimulated EGFR endocytosis is greatly inhibited; microinjection of ErbB2 expression plasmid into low-ErbB2 cells inhibits EGFR endocytosis; the endocytosis deficiency maps to ErbB2's intracellular domain.\",\n      \"method\": \"Subcellular fractionation, co-immunoprecipitation, indirect immunofluorescence, microinjection of ErbB2 expression plasmid, ErbB2/EGFR chimera endocytosis assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, domain mapping with chimeric receptor, replicated in four cell lines\",\n      \"pmids\": [\"10233167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EGF crosses the blood-brain barrier rapidly (influx rate ~2 μl/g·min) via a saturable transport system distinct from the EGFR; the transport is competed by unlabeled EGF and TGF-α but not by anti-EGFR antibody or by EGFR mutation, suggesting a separate EGF transport receptor at the BBB.\",\n      \"method\": \"Intravenous injection of 125I-EGF in mice with competition experiments; mice with EGFR mutations; TCA precipitation of brain-recovered peptide\",\n      \"journal\": \"Peptides\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — saturation kinetics with competition experiments and genetic model\",\n      \"pmids\": [\"10499427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The EGF receptor extracellular region exists in an autoinhibited 'tethered' conformation where the dimerization arm in domain II is occluded by intramolecular interactions with domain IV; EGF binding to domains I and III promotes a large domain rearrangement exposing the dimerization interface for receptor-mediated dimerization.\",\n      \"method\": \"X-ray crystallography at 2.8 Å of unliganded sEGFR extracellular region; mutagenesis validation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis validation, highly cited foundational structure paper\",\n      \"pmids\": [\"12620237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Crystal structure of the 2:2 EGF:EGFR extracellular domain complex at 3.3 Å reveals: EGF docks between EGFR domains I and III; receptor dimerization occurs through a direct receptor-receptor interaction mediated by a protruding β-hairpin arm from domain II of each monomer; dimerization is receptor-mediated, not ligand-mediated. Validated by EGFR mutagenesis.\",\n      \"method\": \"X-ray crystallography at 3.3 Å resolution, EGFR mutagenesis to verify dimerization interface\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis, highly cited landmark structural paper\",\n      \"pmids\": [\"12297050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Decorin binds to EGFR at a narrow region within the L2 domain (residues His394–Ile402) that partially overlaps with but is distinct from the EGF-binding site (K465 required for EGF but not decorin binding); decorin binding antagonizes EGFR tyrosine kinase. Central LRR6 of decorin mediates EGFR interaction.\",\n      \"method\": \"Decorin/alkaline phosphatase chimera, cDNA library expression cloning, yeast two-hybrid, EGF competition assays, EGFR deletion mutants, site-directed mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods including mutagenesis and expression cloning\",\n      \"pmids\": [\"12105206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cbl recruits CIN85 (constitutively bound to endophilins) to form a complex with activated EGFR upon EGF stimulation, controlling receptor internalization via clathrin-coated vesicles. This mechanism is functionally separable from Cbl's ubiquitin ligase activity: blocking CIN85-endophilin interaction inhibits EGFR internalization and delays degradation without affecting receptor ubiquitination.\",\n      \"method\": \"Co-immunoprecipitation, dominant-negative and siRNA approaches, internalization assays, ubiquitination assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with multiple orthogonal methods separating ubiquitination from endocytosis\",\n      \"pmids\": [\"11894095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Cisplatin activates EGFR in a ligand-independent manner requiring EGFR kinase activity; this activation is mediated by c-Src kinases (blocked by Src inhibitor PP1 and dominant-negative kinase-dead receptor); EGFR activation by cisplatin represents a survival response, as EGFR inhibition enhances cisplatin-induced cell death.\",\n      \"method\": \"EGFR phosphorylation assays, kinase inhibitor (EGFR and Src), kinase-dead EGFR expression, cell death assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pharmacological and genetic tools, functional survival readout\",\n      \"pmids\": [\"12483525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Laminin-5 domain III (DIII), liberated by matrix metalloproteinases during mammary gland involution, binds to EGFR and stimulates downstream MAPK signaling, MMP-2 gene expression, and cell migration. This ECM fragment functions as a cryptic EGFR ligand in tissue remodeling.\",\n      \"method\": \"Recombinant DIII binding to EGFR, downstream MAPK signaling measurement, MMP-2 expression, cell migration assay, TIMP-3 knockout mouse model\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — recombinant protein binding with functional readouts and in vivo validation in knockout mouse\",\n      \"pmids\": [\"12695504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"H. pylori induces HB-EGF gene expression and EGFR transactivation through the 'triple membrane passing signal' (TMPS): H. pylori triggers metalloprotease cleavage of surface HB-EGF precursor, releasing soluble HB-EGF that activates EGFR; this cascade requires metalloprotease, EGFR, and MEK1 activities and enhances IL-8 production.\",\n      \"method\": \"EGFR phosphorylation assays with metalloprotease inhibitors, HB-EGF gene expression analysis, IL-8 release measurement in gastric cancer cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway inhibitor dissection with multiple readouts\",\n      \"pmids\": [\"12099696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"ADAM12 metalloprotease specifically sheds HB-EGF in cardiomyocytes stimulated by GPCR agonists; dominant-negative ADAM12 abrogates HB-EGF shedding and EGFR transactivation; KB-R7785 inhibitor binds ADAM12 directly; this pathway mediates cardiac hypertrophy. Identifies ADAM12 as the specific enzyme for cardiac HB-EGF shedding.\",\n      \"method\": \"ADAM12 cloning, dominant-negative expression, direct binding of KB-R7785 to ADAM12, EGFR phosphorylation, cardiac hypertrophy model in mice\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods including dominant-negative, direct binding, and in vivo mouse model\",\n      \"pmids\": [\"11786904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"SHP2 acts upstream of Ras in EGFR signaling by dephosphorylating RasGAP binding sites at the plasma membrane (specifically Tyr992 of EGFR), preventing RasGAP membrane translocation and thereby extending the half-life of GTP-Ras and enhancing Ras-dependent mitogenic signaling.\",\n      \"method\": \"Dominant-negative SHP2, EGFR Y992F point mutation, RasGAP translocation assay, GTP-Ras half-life measurement\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — site-directed mutagenesis of specific EGFR residue with mechanistic pathway analysis\",\n      \"pmids\": [\"14560030\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CAML (calcium-modulating cyclophilin ligand) directly associates with the kinase domain of EGFR in a ligand-dependent manner and is required for efficient recycling of internalized EGFR to the plasma membrane; CAML-deficient cells show impaired EGF-induced proliferation despite normal EGF-induced signaling and internalization.\",\n      \"method\": \"CAML gene disruption in mice, EGF-stimulated proliferation assay, EGFR internalization assay, direct CAML-EGFR association by co-immunoprecipitation\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockout with mechanistic follow-up showing direct protein interaction\",\n      \"pmids\": [\"12919676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Gab1 associates with EGFR at pTyr1068 and pTyr1086 in the receptor C-tail; Gab1 overexpression potentiates EGF-induced MAPK and JNK activation; PI3K (via its product PtdIns(3,4,5)P3 binding to Gab1 PH domain) acts as both upstream regulator and downstream effector of Gab1, creating a positive feedback loop; PTEN lipid phosphatase blocks this loop.\",\n      \"method\": \"Co-immunoprecipitation, GST-pulldown mapping, dominant-interfering p85, Wortmannin, PH domain-PIP3 binding, PTEN expression, GFP-Gab1 translocation imaging\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal approaches defining site of interaction and positive feedback mechanism\",\n      \"pmids\": [\"10648629\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"EGF-induced actin polymerization remains locally restricted at the site of EGF bead stimulation (requires Arp2/3 complex and cofilin, independent of PI3K and Rho), while EGF-induced ERK activation spreads throughout the cell, demonstrating spatially distinct signaling scales from locally stimulated EGFR.\",\n      \"method\": \"Biotin-EGF streptavidin magnetic bead local stimulation, actin polymerization assay, PI3K and Rho inhibitors, Arp2/3 and cofilin functional analysis, ERK activation imaging\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — novel local stimulation approach with multiple pathway inhibitor experiments\",\n      \"pmids\": [\"12952932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Acetylcholine triggers mitochondrial ROS generation in cardiomyocytes via sequential metalloproteinase-dependent shedding of HB-EGF from the proHB-EGF precursor, followed by EGFR transactivation and PI3K activation; blocking metalloproteinase, HB-EGF (with CRM-197), or EGFR abrogates ROS generation and cardioprotection in intact hearts.\",\n      \"method\": \"MitoTracker Red fluorescence, metalloproteinase inhibitor III, CRM-197 HB-EGF inhibitor, anti-HB-EGF neutralizing antibody, EGFR phosphorylation in perfused hearts, infarct size measurement\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors in both cell and intact heart models\",\n      \"pmids\": [\"15010282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Cetuximab inhibits EGFR by binding exclusively to domain III of the EGFR extracellular region (in its autoinhibited tethered conformation), partially occluding the EGF ligand-binding region and sterically preventing the receptor from adopting the extended conformation required for dimerization.\",\n      \"method\": \"X-ray crystallography at 2.8 Å of cetuximab Fab–sEGFR complex\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure defining precise mechanism of antibody inhibition\",\n      \"pmids\": [\"15837620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Nuclear EGFR physically interacts with STAT3 in the nucleus, and this complex directly activates transcription of the iNOS gene; nuclear EGFR abundance positively correlates with iNOS levels in breast carcinomas; this reveals a transcription factor mode of action for nuclear EGFR requiring STAT3 as a DNA-binding co-factor.\",\n      \"method\": \"Co-immunoprecipitation of nuclear EGFR and STAT3, chromatin immunoprecipitation, reporter gene assays, IHC in breast carcinomas\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + Co-IP + reporter assay + in vivo correlation, multiple orthogonal methods\",\n      \"pmids\": [\"15950906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Lung cancer EGFR mutations (L858R, G719S) activate EGFR by disrupting autoinhibitory interactions between the activation loop and αC helix in the kinase domain; L858R accelerates catalysis up to 50-fold in vitro; gefitinib binds 20-fold more tightly to L858R mutant than wild-type; crystal structures show similar inhibitor binding modes for gefitinib and AEE788 but a staurosporine rotation in G719S.\",\n      \"method\": \"Crystal structures of mutant kinases with inhibitors, in vitro kinase activity measurement, direct binding measurements by fluorescence\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures + in vitro kinase assays + direct binding measurements, highly cited\",\n      \"pmids\": [\"17349580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Somatic EGFR mutations found in gefitinib-sensitive NSCLC (e.g., L858R, exon 19 deletions) cause EGF-independent constitutive EGFR signaling; mutant receptors at the cell surface are fully competent to bind EGF; mutations predicted to disrupt activation loop-αC helix autoinhibitory interactions elevate ligand-independent kinase activity.\",\n      \"method\": \"Expression of EGFR mutants in null background (NR6 cells), EGF-independent Ba/F3 cell mitogenesis assay, tyrosine phosphorylation analysis, EGF binding assay\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — null background expression with functional mitogenesis and biochemical readouts\",\n      \"pmids\": [\"16953218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Rabring7, a Rab7-interacting RING finger domain protein, has E3 ubiquitin ligase activity (preferentially using Ubc4/Ubc5 as E2 enzymes) and accelerates ligand-induced EGFR degradation; a catalytic mutant (C229S) inhibits cCbl-induced EGFR degradation, demonstrating Rabring7 participates in late endocytic trafficking of EGFR through its E3 ligase activity.\",\n      \"method\": \"In vitro ubiquitination assay with recombinant E1/E2/E3, RING domain mutagenesis, EGFR degradation assay with wild-type and C229S Rabring7\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro ubiquitination reconstitution plus cellular degradation assay\",\n      \"pmids\": [\"17462600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"EGF increases TRPM6 Mg2+ channel activity and plasma membrane surface expression through a pathway involving Src family tyrosine kinases and downstream Rac1; constitutively active Rac1 mimics EGF effects; dominant-negative Rac1 abrogates EGF-stimulated TRPM6 activity; the TRPM6 alpha-kinase domain is not required.\",\n      \"method\": \"Whole-cell patch-clamp recording of TRPM6, dominant-negative and constitutively active Rac1 expression, FRAP for TRPM6 mobility, Src inhibitor experiments in HEK293 cells\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — electrophysiology + genetic tools (dominant-negative/constitutively active Rac1) + FRAP, multiple orthogonal methods\",\n      \"pmids\": [\"19073827\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARAP1, a multidomain protein with Arf GAP and Rho GAP activities, localizes to endosomal compartments (including internal membranes of multivesicular bodies) and controls late steps of EGFR endocytic trafficking; ARAP1 knockdown causes EGFR accumulation in sorting/late endosomes and inhibits EGFR degradation with prolonged signaling.\",\n      \"method\": \"siRNA knockdown, ARAP1 localization by immunofluorescence/immunoelectron microscopy, EGFR trafficking and degradation assays\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNAi knockdown with defined trafficking phenotype and signaling readout\",\n      \"pmids\": [\"18764928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The intracellular juxtamembrane domain of EGFR is required for both negative cooperativity in EGF binding and for the positive linkage between EGF binding and receptor dimerization; autophosphorylation abolishes the positive linkage but not cooperativity; this reveals inside-out signaling where intracellular events regulate extracellular ligand binding.\",\n      \"method\": \"Equilibrium EGF binding analysis with multiple EGFR mutants (juxtamembrane deletions, autophosphorylation site mutants), quantitative binding modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutant analysis with quantitative binding model\",\n      \"pmids\": [\"19336395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Tom1L1 is transiently tyrosine-phosphorylated by Src family kinases upon EGF stimulation and forms a complex with activated EGFR bridged by Grb2 and Shc; Tom1L1 contains a novel clathrin-interacting motif in its C-terminal tail that engages clathrin heavy chain; RNAi knockdown of Tom1L1 inhibits EGFR endocytosis, identifying Tom1L1 as an adaptor linking activated EGFR to clathrin endocytic machinery.\",\n      \"method\": \"RNAi knockdown, co-immunoprecipitation, tyrosine phosphorylation assay, clathrin binding domain mapping, dominant-negative mutants\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNAi, reciprocal Co-IP, domain mapping, and functional rescue experiments\",\n      \"pmids\": [\"19798056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Ganglioside GM3 strongly inhibits EGFR kinase domain autophosphorylation in a membrane context; this inhibition requires membrane phase separation and is released by removing GM3's neuraminic acid headgroup or by mutating EGFR membrane-proximal lysine K642G; GM3 prevents the allosteric transition from inactive to signaling EGFR dimer.\",\n      \"method\": \"Reconstitution of EGFR in proteoliposomes of defined lipid composition, autophosphorylation assay, headgroup modification, K642G mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — minimal reconstitution system with purified EGFR in defined lipid environment, mutagenesis validation\",\n      \"pmids\": [\"21571640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IQGAP1 scaffold protein directly associates with EGFR (via its IQ domain binding to EGFR kinase domain) independent of EGF stimulation; calmodulin disrupts this interaction; IQGAP1-null cells show severely attenuated EGF-stimulated EGFR autophosphorylation; IQGAP1 S1443 (phosphorylated by PKCα downstream of EGFR) modulates EGFR activation.\",\n      \"method\": \"Co-immunoprecipitation (endogenous proteins), in vitro direct association assay, mass spectrometry phosphorylation mapping, IQGAP1 null cells with reconstitution, siRNA knockdown of PKCα\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vitro association + co-IP of endogenous proteins + null cell reconstitution + MS phosphorylation mapping\",\n      \"pmids\": [\"21349850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The EGF transcriptional response is primarily elicited by EGFR at the cell surface, not from endosomes: keeping EGFR at the cell surface (by blocking endocytosis or ubiquitination) increases EGF-induced transcript abundance, while ESCRT depletion (trapping EGFR in endosomes with enhanced kinase activity) has little effect on the transcriptional profile.\",\n      \"method\": \"ESCRT depletion (siRNA), inhibition of EGFR endocytosis and ubiquitination, transcriptome profiling, kinase activity measurement\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic genetic perturbations of trafficking with transcriptome readout\",\n      \"pmids\": [\"22416276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Annexin A1 interaction with S100A11 in endosomes is required for efficient lysosomal targeting of EGFR: a dominant-negative N-terminal truncation of annexin A1 (lacking both the EGFR phosphorylation site and S100A11 binding site) delays EGFR transport to LAMP1+ compartments and prolongs EGFR/MAPK signaling; S100A11 depletion produces the same trafficking defect.\",\n      \"method\": \"Dominant-negative annexin A1 mutant overexpression, S100A11 siRNA, EGFR trafficking assays, EGFR degradation and MAPK signaling measurements\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative mutant + siRNA with parallel trafficking phenotypes\",\n      \"pmids\": [\"23246849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Following EGF or ionomycin treatment, rhomboid intramembrane proteases (not γ-secretase) cleave the EGFR to produce a ~60 kDa intracellular domain (ICD) fragment present in both membrane and nuclear fractions; calpain inhibition increases detectable ICD levels; this regulated intramembrane cleavage occurs slowly over 3–24 hours.\",\n      \"method\": \"Chemical inhibitor profiling (γ-secretase vs. rhomboid inhibitors), rhomboid cDNA overexpression, calpain inhibitor, subcellular fractionation of ICD fragment in A431 cells\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection combined with overexpression of specific protease\",\n      \"pmids\": [\"22531034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Molecular dynamics simulations of membrane-embedded EGFR show that in ligand-bound dimers, extracellular domains favor N-terminal transmembrane helix dimerization and asymmetric (active) kinase dimer formation; in ligand-free dimers, extracellular domains favor C-terminal transmembrane dimerization, juxtamembrane burial, and symmetric (inactive) kinase dimers; electrostatic membrane interactions of the intracellular module are critical for this coupling.\",\n      \"method\": \"Molecular dynamics simulations of full-length membrane-embedded EGFR\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational prediction only, no direct experimental validation in this study\",\n      \"pmids\": [\"23374350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EGFR is fully activated by EGF during mitosis (all five major tyrosine residues phosphorylated equivalently to interphase); however, in mitosis EGFR selectively activates PI3K, AKT2 (not AKT1), c-Src, c-Cbl, and PLCγ1 but cannot activate ERK1/2 because Raf-1 is not fully activated (lacks pY341, retains pS259); EGFR-dependent endocytosis during M phase requires EGFR kinase activity (unlike in interphase).\",\n      \"method\": \"EGF stimulation of synchronized mitotic cells, phosphorylation assays for EGFR and multiple downstream effectors, EGFR endocytosis assay in M phase vs. interphase\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic phosphorylation mapping of multiple effectors in synchronized cells\",\n      \"pmids\": [\"25479591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"EGFR ligands EGF, epiregulin (EREG), and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region; EREG and EPGN act as partial agonists of EGFR dimerization (inducing less stable dimers than EGF) and elicit more sustained EGFR signaling and differentiation-associated responses in breast cancer cells, rather than the proliferative response induced by EGF.\",\n      \"method\": \"X-ray crystallography of EGFR extracellular domain with different ligands, single-molecule imaging of EGFR dimerization, phosphorylation and signaling dynamics assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus single-molecule dimerization measurements plus functional signaling assays\",\n      \"pmids\": [\"28988771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"EGF-stimulated phosphorylation of histone H3 requires Rsk-2 (pp90rsk family kinase); fibroblasts from Coffin-Lowry syndrome patients (RSK-2 mutations) fail to show EGF-stimulated H3 phosphorylation; RSK-2 gene disruption in ES cells abolishes EGF-stimulated H3 phosphorylation; H3 appears to be a direct or indirect Rsk-2 target, linking EGF/MAPK signaling to chromatin remodeling.\",\n      \"method\": \"Coffin-Lowry patient fibroblasts, RSK-2 gene KO in ES cells, RSK-2 cDNA rescue, EGF stimulation with H3 phosphorylation assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient cells, gene knockout, and rescue experiments, multiple independent genetic approaches\",\n      \"pmids\": [\"10436156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1983,\n      \"finding\": \"Human EGF/beta-urogastrone in plasma is associated with blood platelets: it is present in platelet-rich plasma and platelet fraction of whole blood; platelets contain both mature EGF and a high-molecular weight precursor form (cleaved to EGF by arginine esterase or trypsin); platelet-associated EGF is released during coagulation.\",\n      \"method\": \"Immunoaffinity chromatography extraction from plasma fractions, Sephadex G-50 gel chromatography, radioimmunoassay, radioreceptor assay, enzymatic cleavage\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical fractionation and characterization, highly cited foundational paper identifying EGF storage site in blood\",\n      \"pmids\": [\"6603475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"EGF triggers nuclear calcium signaling through PLCδ4 (not PLCγ1): nuclear EGFR hydrolyzes nuclear PI(4,5)P2 via PLCδ4, releasing InsP3 that activates InsP3 receptors on the nucleoplasmic reticulum to release Ca2+; nuclear Ca2+ signaling requires EGFR nuclear translocation; PLCδ4 and InsP3 modulate cell cycle progression by regulating cyclin A and B1 expression.\",\n      \"method\": \"Subcellular fractionation, siRNA knockdown of PLCδ4 and PLCγ1, FRET-based InsP3 biosensor, EGFR nuclear translocation inhibition, cyclin expression analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple knockdowns with FRET biosensor and cell cycle readout\",\n      \"pmids\": [\"31537645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"EGF/PKB-Akt signaling promotes FOXO4 degradation via a CSN6-COP1 axis: EGF treatment elevates CSN6 and COP1 levels; CSN6 binds FOXO4 and enhances COP1 E3 ligase activity toward FOXO4; COP1 directly interacts with FOXO4 via a VP motif and accelerates ubiquitin-mediated FOXO4 degradation; this reduces FOXO4-mediated suppression of serine-glycine-one-carbon (SGOC) metabolic pathway genes.\",\n      \"method\": \"Co-immunoprecipitation (CSN6-FOXO4 and COP1-FOXO4), ubiquitination assay, COP1 E3 ligase activity assay, ChIP for FOXO4 binding to SGOC gene promoters, metabolomic analysis\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP + in vitro ubiquitination + ChIP + metabolomics\",\n      \"pmids\": [\"33101846\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"EGF is a 53-amino-acid polypeptide (derived from a 1,207-aa transmembrane precursor) that binds to EGFR domains I and III, releasing intramolecular autoinhibition of the extracellular region and driving receptor-mediated dimerization via domain II β-hairpin arms; dimerization activates the asymmetric intracellular kinase, which transphosphorylates partner receptors on multiple C-tail tyrosines that serve as docking sites for SH2-domain adaptors (Grb2, Shc, p85/PI3K, PLCγ, SHP2, Gab1) to initiate Ras/MAPK, PI3K/Akt, PLCγ/Ca2+, and nuclear signaling cascades; receptor trafficking (clathrin-mediated endocytosis facilitated by Cbl-CIN85-endophilin and Tom1L1, recycling via CAML, late endosomal sorting by Rabring7/Rab7/annexin A1-S100A11, and rhomboid-mediated intramembrane cleavage) controls signal duration and amplitude; ligand identity (EGF vs. EREG/EPGN) determines dimer stability and signaling kinetics; membrane lipids (GM3 ganglioside) and scaffolds (IQGAP1, caveolin) modulate kinase activation; nuclear EGFR cooperates with STAT3 to activate iNOS transcription, and EGF-activated Rsk-2 phosphorylates histone H3 to remodel chromatin.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"EGF is a mitogenic ligand that activates the EGF receptor (EGFR) by binding its extracellular domain, inducing receptor dimerization and intermolecular trans-autophosphorylation of the intracellular tyrosine kinase domain, with the juxtamembrane segment mediating allosteric coupling between ligand binding and kinase activation [PMID:6264233, PMID:2164634, PMID:19336395]. Activated EGFR directly phosphorylates PLCγ to stimulate PIP2 hydrolysis, IP3 generation, and Ca²⁺ release, recruits adaptors Grb2 and Shc to initiate MAP kinase signaling and clathrin-mediated endocytosis via Tom1L1, and undergoes rhomboid-mediated intramembrane cleavage producing a nuclear ICD that activates PLCδ4 for nuclear Ca²⁺ signaling and cell cycle progression [PMID:2472218, PMID:11956311, PMID:19798056, PMID:31537645, PMID:22531034]. EGFR signaling is attenuated by GM3 ganglioside-dependent inhibition of kinase activation in the membrane, PKC-mediated Thr654 phosphorylation regulating internalization kinetics, and ubiquitin-dependent lysosomal degradation facilitated by the annexin A1/S100A11 complex and the E3 ligase Rabring7 in multivesicular bodies [PMID:21571640, PMID:1556153, PMID:23246849, PMID:17462600]. EGF also feedforward-stabilizes EGFR mRNA to replenish receptors consumed by ligand-induced degradation, and somatic EGFR kinase domain mutations that disrupt autoinhibition cause constitutive activation linked to gefitinib-sensitive non-small-cell lung cancer [PMID:2420792, PMID:16953218].\",\n  \"teleology\": [\n    {\n      \"year\": 1980,\n      \"claim\": \"Establishing that EGFR is a transmembrane protein with an extracellular ligand-binding site and a cytoplasmic kinase domain resolved how EGF signals across the membrane.\",\n      \"evidence\": \"Controlled proteolysis and EGF crosslinking of A431 cell membranes with permeabilization-dependent phosphorylation\",\n      \"pmids\": [\"6264233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor stoichiometry and oligomeric state upon ligand binding unknown\", \"Kinase substrate identity unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Mapping the endocytic itinerary of EGF-EGFR complexes from peripheral endosomes through multivesicular bodies to lysosomes established the receptor degradation route and explained ligand-induced receptor downregulation.\",\n      \"evidence\": \"HRP-EGF EM, immunogold, acid phosphatase cytochemistry, and temperature-shift experiments in A431 cells\",\n      \"pmids\": [\"2868013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery (ubiquitin, ESCRT) driving MVB sorting not yet identified\", \"Whether signaling continues from endosomes was unknown\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Demonstrating that EGF stimulates EGFR mRNA accumulation revealed a feedforward loop compensating for ligand-induced receptor loss, later shown to operate through mRNA stabilization.\",\n      \"evidence\": \"Metabolic labeling, immunoprecipitation, Northern blot (1986); actinomycin D mRNA decay assay (1988)\",\n      \"pmids\": [\"2420792\", \"3260374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RNA-binding proteins and cis-elements mediating stabilization unidentified\", \"Whether this loop operates in vivo at physiological EGF concentrations unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Identifying PLCγ (PLC-II) as a direct tyrosine-phosphorylated EGFR substrate that co-immunoprecipitates with the receptor linked EGFR kinase activity to PIP2 hydrolysis and Ca²⁺ mobilization.\",\n      \"evidence\": \"Anti-phosphotyrosine immunoblotting, co-IP, and kinase inhibitor treatment across multiple cell types\",\n      \"pmids\": [\"2472218\", \"3030297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation sites on PLCγ required for activation not mapped\", \"Relative contribution of PLCγ versus other effectors to mitogenesis unclear\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Proving that EGFR autophosphorylation occurs by intermolecular trans-phosphorylation established dimerization as the activating event and explained how kinase-dead receptors act as dominant negatives.\",\n      \"evidence\": \"Co-expression of kinase-dead K721A and wild-type EGFR with immunoprecipitation and mitogenic readout\",\n      \"pmids\": [\"2164634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of asymmetric kinase dimer not yet determined\", \"Whether higher-order oligomers contribute was unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Quantitative analysis of EGFR internalization kinetics and identification of the Thr654 PKC site and kinase activity as regulators of endocytic rate revealed how signaling feeds back on receptor trafficking.\",\n      \"evidence\": \"Internalization kinetics with kinase-dead and Thr654 mutant receptors, phorbol ester treatment\",\n      \"pmids\": [\"1556153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between Thr654 phosphorylation and clathrin machinery not defined\", \"Role of non-clathrin pathways at high EGF doses unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showing that sustained nuclear MAP kinase activation by overexpressed EGFR is sufficient for PC12 neuronal differentiation demonstrated that signal duration and compartmentalization, not pathway identity, determine cell fate.\",\n      \"evidence\": \"EGFR overexpression in PC12 cells with MAP kinase activity assays, nuclear translocation immunofluorescence, and differentiation morphology\",\n      \"pmids\": [\"7953555\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Nuclear MAP kinase substrates mediating differentiation genes not identified\", \"Whether this principle generalizes beyond PC12 cells unclear\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of Arg-45 as the critical residue for EGF binding specificity versus TGFα defined the molecular determinants of the ligand-receptor interface.\",\n      \"evidence\": \"EGF/TGFα chimeras and R45A point mutant competitive binding assays on chicken EGFR\",\n      \"pmids\": [\"7673217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the Arg-45 contact not crystallographically resolved at the time\", \"Species-specific differences in receptor binding not fully explored\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Systematic mapping of ErbB heterodimer ligand-binding specificity and the discovery that ErbB2 co-expression impairs EGFR endocytosis established how receptor composition tunes both signal input and signal duration.\",\n      \"evidence\": \"Soluble receptor binding assays for 11 ligands across ErbB combinations (1999); domain-swap chimeras and fractionation for endocytosis defect (1999)\",\n      \"pmids\": [\"10214951\", \"10233167\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of ErbB2 endocytosis resistance not resolved\", \"Quantitative impact on downstream signaling networks not modeled\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Multiple studies converged on EGFR transactivation mechanisms: Grb2 recruitment to EGFR via SH2 domain and coupling to endocytic machinery via SH3, H. pylori-induced metalloprotease-dependent HB-EGF shedding as a triple membrane-passing signal, cisplatin-induced ligand-independent EGFR activation via Src kinases, and decorin as an EGFR antagonist binding at a partially overlapping site.\",\n      \"evidence\": \"Live-cell GFP-Grb2 imaging with domain mutants; HB-EGF shedding assays with metalloprotease/MEK inhibitors; cisplatin with Src inhibitor/kinase-dead epistasis; decorin binding with yeast two-hybrid and site-directed mutagenesis\",\n      \"pmids\": [\"11956311\", \"12099696\", \"12483525\", \"12105206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Grb2-mediated macropinocytic and clathrin-dependent routes operate simultaneously in vivo\", \"Complete structural model of decorin-EGFR interface lacking\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of Rabring7 as a RING-finger E3 ubiquitin ligase that cooperates with Cbl to accelerate EGFR degradation placed a second E3 in the endosomal sorting pathway.\",\n      \"evidence\": \"In vitro ubiquitination reconstitution with E1/E2, RING-finger C229S mutagenesis, cellular EGFR degradation assay\",\n      \"pmids\": [\"17462600\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Rabring7 directly ubiquitinates EGFR or acts on endosomal adaptors unclear\", \"Relationship to ESCRT-dependent sorting not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that the juxtamembrane domain mediates negative cooperativity in EGF binding and that autophosphorylation abolishes positive linkage between binding and dimerization revealed inside-out regulation of the extracellular domain by intracellular events.\",\n      \"evidence\": \"Systematic JM deletion and phospho-site mutants with quantitative EGF binding analysis\",\n      \"pmids\": [\"19336395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism of inside-out conformational change not directly visualized\", \"Whether this cooperativity operates identically for other EGF-family ligands unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Tom1L1 was identified as an Src-phosphorylated adaptor that bridges activated EGFR (via Grb2/Shc) to clathrin heavy chain, providing a molecular mechanism coupling kinase signaling to clathrin-mediated endocytosis.\",\n      \"evidence\": \"Co-IP, RNAi, dominant-negative mutants, and clathrin-binding motif mapping\",\n      \"pmids\": [\"19798056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry of the EGFR-Grb2/Shc-Tom1L1-clathrin complex not determined\", \"Whether Tom1L1 is rate-limiting versus redundant with other clathrin adaptors unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reconstitution of EGFR in proteoliposomes showed that GM3 ganglioside inhibits kinase activation by preventing the allosteric transition to the active dimer, dependent on membrane phase separation and Lys642, establishing lipid-mediated regulation of receptor signaling.\",\n      \"evidence\": \"Defined-lipid proteoliposome reconstitution with autophosphorylation assay, neuraminidase treatment, K642G mutagenesis\",\n      \"pmids\": [\"21571640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GM3 inhibition occurs in physiological plasma membrane lipid compositions not tested in living cells\", \"Structural basis of K642-GM3 interaction not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Three concurrent advances refined EGFR signal-trafficking coupling: (1) the transcriptional response is primarily elicited from the cell surface, not endosomes; (2) the annexin A1/S100A11 complex facilitates MVB inward vesiculation and EGFR lysosomal delivery; (3) rhomboid intramembrane proteolysis releases a nuclear EGFR ICD fragment.\",\n      \"evidence\": \"ESCRT/ubiquitin RNAi with transcriptomics; annexin A1 truncation mutant and S100A11 RNAi with trafficking assays; chemical inhibitor profiling and rhomboid overexpression with subcellular fractionation\",\n      \"pmids\": [\"22416276\", \"23246849\", \"22531034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Rhomboid-cleaved ICD's nuclear targets beyond PLCδ4 uncharacterized\", \"Whether surface versus endosomal signaling distinction holds for all EGFR-dependent transcriptional programs unknown\", \"Rhomboid cleavage evidence is from a single lab with pharmacological/overexpression approach\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Nuclear EGFR activates PLCδ4 (not PLCγ1) to hydrolyze nuclear PI(4,5)P2, generating nuclear InsP3 and Ca²⁺ release from the nucleoplasmic reticulum, which drives nuclear PKC activation and cyclin A/B1 expression for cell cycle progression.\",\n      \"evidence\": \"Subcellular fractionation, PLCδ4 siRNA, FRET-based nuclear Ca²⁺ biosensors, nuclear InsP3 buffering, cyclin expression analysis\",\n      \"pmids\": [\"31537645\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nuclear EGFR specifically activates PLCδ4 is mechanistically unclear\", \"Whether nuclear Ca²⁺ signaling is required for EGFR-driven proliferation in vivo not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full structural basis of inside-out allosteric coupling across the membrane, the identity of RNA-binding proteins mediating EGF-induced EGFR mRNA stabilization, and the physiological significance of nuclear EGFR ICD signaling in normal tissue homeostasis versus cancer.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No full-length EGFR structure in a native membrane context\", \"RNA stabilization machinery not identified\", \"In vivo relevance of nuclear EGFR signaling arm untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 7, 8, 30]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [16, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [30, 9, 13]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [6, 24, 26]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [27, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 2, 7, 8, 11, 17, 19, 22, 28]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [6, 15, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [28]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [6, 10, 24, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"EGFR\", \"GRB2\", \"PLCG1\", \"IQGAP1\", \"TOM1L1\", \"ANXA1\", \"S100A11\", \"CAML\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"EGF is a mitogenic polypeptide derived by proteolytic processing from a 1,207-amino-acid transmembrane precursor; it binds EGFR extracellular domains I and III, releasing an autoinhibited tethered conformation and exposing a domain II β-hairpin dimerization arm that drives receptor-mediated dimerization and asymmetric kinase activation via intermolecular transphosphorylation [PMID:12297050, PMID:12620237, PMID:2164634]. Receptor C-tail phosphotyrosines recruit SH2-domain adaptors (PLCγ, PI3K p85, Shc/Grb2, Gab1, SHP2) to activate Ras/MAPK, PI3K/Akt, and PLCγ/Ca²⁺ cascades, with signal duration—controlled by ligand identity, dimer stability, and receptor trafficking through clathrin-mediated endocytosis (via Cbl–CIN85–endophilin and Tom1L1) and recycling (via CAML)—determining whether EGF elicits proliferative or differentiative outcomes [PMID:2472218, PMID:1372091, PMID:10648629, PMID:7953555, PMID:11894095, PMID:19798056, PMID:28988771]. Membrane lipid environment (GM3 ganglioside inhibits the allosteric kinase transition) and scaffold proteins (IQGAP1) modulate activation thresholds, while nuclear-translocated EGFR cooperates with STAT3 to drive iNOS transcription and EGF-activated Rsk-2 phosphorylates histone H3 to remodel chromatin [PMID:21571640, PMID:21349850, PMID:15950906, PMID:10436156]. EGF is stored in platelets and released during coagulation, and its precursor is expressed as a cell-surface transmembrane protein whose biology is co-opted by GPCR transactivation pathways involving metalloproteinase-mediated shedding of HB-EGF [PMID:6603475, PMID:11786904, PMID:9020193].\",\n  \"teleology\": [\n    {\n      \"year\": 1980,\n      \"claim\": \"Establishing that EGF acts across the membrane resolved the fundamental topology question—EGF binds extracellularly while its receptor's kinase phosphorylates substrates cytoplasmically, defining EGFR as a transmembrane signaling conduit.\",\n      \"evidence\": \"Controlled proteolysis of intact vs. permeabilized cells with ³²P-ATP labeling\",\n      \"pmids\": [\"6264233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of transmembrane signal transduction unknown\", \"Identity of kinase substrates unresolved\"]\n    },\n    {\n      \"year\": 1983,\n      \"claim\": \"Discovery that platelets store both mature EGF and a high-molecular-weight precursor form revealed a physiological reservoir for circulating EGF and implied regulated proteolytic processing of the precursor.\",\n      \"evidence\": \"Immunoaffinity chromatography and radioimmunoassay of platelet-rich vs. platelet-poor plasma fractions\",\n      \"pmids\": [\"6603475\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for precursor cleavage in vivo not identified\", \"Physiological significance of platelet-derived EGF release in wound healing not directly tested\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Sequencing the full 1,207-residue EGF precursor and demonstrating its endosomal trafficking with EGFR established the biosynthetic origin and the post-binding itinerary of the ligand–receptor complex.\",\n      \"evidence\": \"cDNA sequencing with COS-7 expression (precursor structure); immunoelectron microscopy with HRP-EGF (endosomal co-localization)\",\n      \"pmids\": [\"3491360\", \"2868013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Proteolytic mechanism releasing 53-aa mature EGF from the precursor not identified\", \"Signals controlling endosome-to-lysosome sorting not defined\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Demonstrating that EGFR overexpression confers EGF-dependent transformation and that EGF activates phosphoinositide hydrolysis linked the ligand to both oncogenic potential and second-messenger generation.\",\n      \"evidence\": \"NIH 3T3 focus formation and soft-agar assays with EGFR overexpression; radiolabeled inositol phosphate measurement in multiple cell lines\",\n      \"pmids\": [\"3500791\", \"3030297\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream effectors of IP3/DAG pathway not mapped\", \"Whether transformation requires specific signaling branches unknown\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Identification of PLCγ as a direct EGFR substrate and mapping of a C-terminal internalization domain dissected the receptor's signaling outputs from its trafficking functions.\",\n      \"evidence\": \"Co-immunoprecipitation of PLCγ with EGFR plus tyrphostin blockade; C-terminal deletion mutant series separating internalization from transcription/transformation\",\n      \"pmids\": [\"2472218\", \"2790960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full repertoire of EGFR C-tail phosphosites and their adaptor assignments incomplete\", \"Relationship between internalization and signal termination untested\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Proving that EGFR autophosphorylation occurs by intermolecular transphosphorylation established the dimerization-dependent activation paradigm and explained how kinase-dead receptors act as dominant negatives.\",\n      \"evidence\": \"Co-expression of kinase-negative K721A and C-terminally truncated active EGFR in living cells\",\n      \"pmids\": [\"2164634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for asymmetric kinase activation not yet resolved\", \"Stoichiometry of higher-order oligomers unknown\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Mapping PI3K p85 SH2-domain association with autophosphorylated EGFR and discovering a direct EGFR–F-actin interaction expanded the receptor's signaling repertoire to lipid kinase and cytoskeletal regulation.\",\n      \"evidence\": \"GST-SH2 pulldowns with phosphotyrosine competition (PI3K); purified EGFR–F-actin co-sedimentation with peptide competition and antibody blocking\",\n      \"pmids\": [\"1372091\", \"1383230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional significance of EGFR–actin binding in vivo not demonstrated\", \"Specific EGFR phosphotyrosine residues docking p85 not mapped\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identification of Src-dependent EGFR transactivation by GPCR Gβγ subunits revealed that EGFR integrates signals from heterologous receptor systems, functioning as a signaling hub beyond its canonical ligand inputs.\",\n      \"evidence\": \"Dominant-negative Src and Csk overexpression, autophosphorylation-specific antibodies, GST-Src-SH2 pulldown in COS-7 cells\",\n      \"pmids\": [\"9020193\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of metalloproteinase and shed ligand mediating transactivation not yet defined\", \"Tissue specificity of transactivation pathway unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Systematic ligand-binding analysis across ErbB dimer combinations and discovery that EGF-stimulated Rsk-2 phosphorylates histone H3 defined both the combinatorial receptor logic and a direct chromatin-level output of EGF signaling.\",\n      \"evidence\": \"Soluble receptor–ligand binding with all ErbB combinations; Coffin-Lowry patient fibroblasts and RSK-2 knockout ES cells with EGF-stimulated H3 phosphorylation\",\n      \"pmids\": [\"10214951\", \"10436156\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic loci targeted by H3 phosphorylation downstream of EGF not identified\", \"Whether partial agonist ligands also induce H3 phosphorylation untested\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Crystal structures of unliganded (tethered) and EGF-bound (extended/dimerized) EGFR ectodomain resolved the autoinhibition-to-activation conformational switch at atomic resolution, answering how ligand binding triggers dimerization.\",\n      \"evidence\": \"X-ray crystallography at 2.8 Å (unliganded) and 3.3 Å (2:2 EGF–EGFR complex) with mutagenesis validation\",\n      \"pmids\": [\"12620237\", \"12297050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length receptor structure in membrane context unavailable\", \"Dynamics of tethered-to-extended transition unresolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Multiple discoveries in 2002 defined how EGFR trafficking is controlled: Cbl–CIN85–endophilin complexes drive clathrin-mediated internalization separable from Cbl's ubiquitin ligase activity; SHP2 sustains Ras signaling by dephosphorylating RasGAP-binding sites; and GPCR-triggered metalloproteinase shedding of HB-EGF (by ADAM12) transactivates EGFR in cardiac and gastric contexts.\",\n      \"evidence\": \"Co-IP/siRNA/dominant-negative dissection of CIN85–endophilin; EGFR Y992F mutant with RasGAP translocation assay; dominant-negative ADAM12 in cardiomyocytes and metalloproteinase inhibitor profiling in gastric cells\",\n      \"pmids\": [\"11894095\", \"14560030\", \"11786904\", \"12099696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CIN85 pathway is universal or cell-type-specific not resolved\", \"Full substrate spectrum of SHP2 at the receptor unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that nuclear EGFR cooperates with STAT3 to activate iNOS transcription, and structural determination of how cetuximab locks EGFR in the tethered conformation, established both a non-canonical transcriptional role and the structural basis for therapeutic antibody blockade.\",\n      \"evidence\": \"ChIP + co-IP + reporter assays for nuclear EGFR–STAT3 on iNOS promoter; 2.8 Å crystal structure of cetuximab Fab–sEGFR complex\",\n      \"pmids\": [\"15950906\", \"15837620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide target genes of nuclear EGFR–STAT3 undefined\", \"How EGFR is imported into the nucleus mechanistically unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Characterization of NSCLC-associated EGFR mutations (L858R, exon 19 deletions) revealed they disrupt activation-loop autoinhibition to produce constitutive, ligand-independent kinase activity, and explained the hypersensitivity of these mutants to gefitinib.\",\n      \"evidence\": \"Crystal structures of L858R and G719S kinase domains with inhibitors; Ba/F3 EGF-independent mitogenesis; in vitro kinase assays showing 50-fold increased catalysis for L858R\",\n      \"pmids\": [\"17349580\", \"16953218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Resistance mutations (e.g. T790M) not structurally addressed in these studies\", \"Whether all activating mutants share the same autoinhibition-disruption mechanism untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Tom1L1 was identified as a clathrin-engaging adaptor linking EGF-activated EGFR–Grb2–Shc complexes to the endocytic machinery, adding a required component to the receptor internalization pathway.\",\n      \"evidence\": \"RNAi knockdown of Tom1L1 inhibiting EGFR endocytosis, reciprocal co-IP, clathrin-binding domain mapping\",\n      \"pmids\": [\"19798056\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Tom1L1 is specific to EGFR or shared with other RTKs not tested\", \"Structural basis of Tom1L1–clathrin interaction unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reconstitution of EGFR in proteoliposomes demonstrated that GM3 ganglioside inhibits the allosteric transition to the active kinase dimer through membrane-proximal lysine interactions, establishing membrane lipid composition as a direct regulator of receptor activation.\",\n      \"evidence\": \"Purified EGFR in defined-lipid proteoliposomes, autophosphorylation assay, K642G mutagenesis\",\n      \"pmids\": [\"21571640\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological regulation of local GM3 concentration at the cell surface not addressed\", \"Other lipid species potentially modulating EGFR not tested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structural and single-molecule analyses showed that different EGFR ligands (EGF vs. EREG/EPGN) stabilize distinct dimer conformations of varying stability, directly determining signaling kinetics and cell-fate outcomes, thus establishing a 'biased agonism' paradigm for receptor tyrosine kinases.\",\n      \"evidence\": \"X-ray crystallography of ectodomain with multiple ligands, single-molecule dimer lifetime imaging, phosphorylation dynamics and phenotypic assays in breast cancer cells\",\n      \"pmids\": [\"28988771\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How dimer stability is decoded by intracellular signaling machinery not defined\", \"Whether biased agonism extends to all seven EGFR ligands untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Nuclear EGFR was shown to hydrolyze nuclear PI(4,5)P₂ via PLCδ4 to generate InsP₃ that triggers nucleoplasmic reticulum Ca²⁺ release, linking nuclear EGFR to cell-cycle progression through cyclin A/B1 regulation.\",\n      \"evidence\": \"siRNA knockdown of PLCδ4/PLCγ1, FRET-based InsP₃ biosensor, EGFR nuclear translocation inhibition, cyclin expression analysis\",\n      \"pmids\": [\"31537645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of EGFR nuclear import still unclear\", \"Whether nuclear Ca²⁺ signaling occurs in non-transformed cells not shown\", \"Single study; independent replication in other cell systems needed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A complete structural model of full-length EGFR in its native membrane environment, integrating extracellular conformational switching with transmembrane helix dynamics, juxtamembrane regulation, and asymmetric kinase activation, remains unavailable; the precise mechanisms of EGFR nuclear import and the genome-wide transcriptional program of nuclear EGFR are unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full-length membrane-embedded EGFR structure\", \"Nuclear EGFR import mechanism unknown\", \"Genome-wide nuclear EGFR target genes not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 5, 6, 14, 21, 49]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [20, 21, 49]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [51]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [4, 51]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3, 39]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 6, 9, 12, 14, 15, 21, 28, 30, 38, 49]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [48, 52]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [3, 8, 11, 23, 41]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 35, 36]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [50]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [51]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"EGFR\",\n      \"PLCG1\",\n      \"PIK3R1\",\n      \"GRB2\",\n      \"SHC1\",\n      \"IQGAP1\",\n      \"ERBB2\",\n      \"GAB1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}